Tag: GlobeNewswire

Integrated gas detection for airport GSE, expanded S24 configurations, and SkyVOX battery location with charging alerts strengthen Flux Power’s product portfolio and innovation pipeline through fiscal 2027

VISTA, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Flux Power Holdings, Inc. (NASDAQ: FLUX) (Flux Power), a developer of advanced lithium-ion energy storage solutions and fleet intelligence technology, today announced three product innovations spanning battery safety, expanded material handing applications and connected fleet intelligence. Together, the launches reflect Flux Power’s execution of its strategy to expand the applications it serves, extend its fleet intelligence capabilities and create additional opportunities for growth across material handling and airport ground support equipment (GSE) markets through fiscal 2027 and beyond.

Developed in collaboration with customers and OEM partners, the innovations build upon Flux Power’s integrated portfolio of lithium-ion batteries, battery management systems and SkyEMS® fleet intelligence, creating more opportunities to serve customers across their operations.

Flux Power Adds Integrated Gas Detection to Airport GSE Batteries

Next-generation monitoring goes beyond industry requirements, adding another layer of protection to Flux Power’s proven battery safety architecture.

Flux Power is adding integrated gas detection to its airport GSE battery lines, the next evolution of the multi-layered safety design already built into every Flux Power battery. Going beyond what industry standards require, the sensor continuously monitors conditions inside the battery and communicates directly with Flux Power’s battery management system (BMS). If a potential thermal event is detected, the BMS can alert a CAN-integrated vehicle and automatically shut down power. On batteries equipped with SkyVOX telematics, events are also reported to SkyEMS for real-time visibility, giving operators and ground crews added confidence on busy ramps.

The solution was developed with a major airline and demonstrated at Flux Power’s Vista, California headquarters recently.

“Safety on the ramp is non-negotiable for our airline customers,” said Mark Barmettler, VP of Engineering at Flux Power. “Flux Power’s integrated gas detection gives operators an added layer of protection and real-time visibility, which we believe makes lithium an even easier decision for GSE fleets.”

Initial shipments are expected in the first quarter of calendar 2027, beginning with an airline end user customer. Flux Power is also planning to offer a retrofit program for batteries already in service.

New S24 Configurations Expand Fleet Opportunities

Flux Power continues to expand its flagship S-Series category with two new S24 configurations, giving OEM partners and national account customers one lithium-ion platform across more of their forklift applications:

• Compact-Compartment Configuration: A new truck adapter and charger configuration developed with a national account customer for a leading forklift OEM truck with a compact battery compartment.
• The Heavy Duty S24 for Walkie Stackers: A maximum capacity configuration engineered for walkie stacker trucks, currently undergoing testing and qualification with a major OEM partner.

The new configurations extend the S-Series beyond its core applications to additional truck models and equipment categories. For OEM partners, a broader S-Series means a qualified Flux Power lithium-ion option across more of their truck lineups, making it easier to specify Flux Power and support their dealer networks with a consistent solution.

For current and new customers, it means standardizing more of their fleet on a single battery platform, backed by SkyEMS fleet intelligence, and one service partner across their sites. Flux Power believes the new S24 configurations will increase its potential share of each customer’s fleet and build a broader foundation for potential future commercial growth.

SkyVOX Brings Battery Location and Charging Alerts to Fleets

SkyVOX extends Flux Power’s fleet intelligence capabilities with battery location and intelligent charging alerts. Fleet managers can quickly locate connected batteries and identify which units need charging, helping to reduce time spent searching for equipment and preventing batteries from reaching a low state of charge mid-shift.

The newest addition to the SkyVOX family introduces external cellular and GPS antennas mounted outside the battery enclosure, so signals aren’t blocked when the SkyVOX telemetry device sits deep inside a steel truck compartment. The result is consistent location tracking and reliable event reporting to SkyEMS, even in installations where internal-antenna telematics often lose connection.

Building on the recently launched SkyEMS® 3.0, SkyVOX further connects battery intelligence with day-to-day fleet operations. Industry research has found that locating and dispatching ground support equipment can take 14 minutes per flight, underscoring the opportunity for real-time battery visibility to help crews deploy equipment faster, improve fleet utilization and keep airport operations moving efficiently.

Shipments are expected to begin in the fourth quarter of calendar 2026.

“These innovations advance Flux Power’s growth strategy across three key areas: battery safety, fleet intelligence and expanded equipment applications,” said Krishna Vanka, Chief Executive Officer of Flux Power. “By solving more customer challenges and extending our technology across more of their operations, we believe we’re creating new opportunities to grow our addressable market, deepen customer relationships and strengthen Flux Power’s competitive position. These launches are part of a broader pipeline of innovation we’re planning to advance through fiscal 2027.”

For more information, visit www.fluxpower.com.

About Flux Power

Flux Power (NASDAQ: FLUX) designs, manufactures, and sells advanced lithium-ion energy storage solutions for electrification of a range of industrial and commercial sectors including material handling and airport ground support equipment (GSE). Flux Power’s lithium-ion battery packs, including the proprietary battery management system (BMS) and telemetry, provide customers with a better performing, lower cost of ownership, and more environmentally friendly alternative, in many instances, to traditional lead acid and propane-based solutions. Lithium-ion battery packs reduce CO2 emissions and help improve sustainability and ESG metrics for fleets. For more information, please visit www.fluxpower.com.

Forward-Looking Statements
This release contains projections and other “forward-looking statements” relating to Flux Power’s business, that are often identified using “believes,” “expects” or similar expressions. Forward-looking statements include, but are not limited to, statements regarding Flux Power’s product roadmap, planned product introductions and planned pipeline of innovation through fiscal 2027, the expected shipment timing of its gas-sensing GSE batteries and SkyVOX telematics units, the planned rollout with its airline partner, any potential retrofitting of existing customer batteries, the outcome of OEM testing and qualification, the new S24 configurations increasing Flux Power’s potential share of each customer’s fleet, future product announcements, expected customer adoption of new products, and quotes from management. Forward-looking statements involve several estimates, assumptions, risks, and other uncertainties that may cause actual results to be materially different from those anticipated, believed, estimated, expected, etc. Accordingly, forward-looking statements are not guarantees of future results. Some of the important factors that could cause Flux Power’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: Flux Power’s ability to amend the terms of its agreement with Gibraltar Business Capital, LLC and Flux Power’s continued access to its credit facility thereunder; Flux Power’s ability to secure sufficient funding to support its current and proposed operations; Flux Power’s ability to continue as a going concern; Flux Power’s ability to meet projected revenue targets and generate sufficient cash from operations; Flux Power’s ability to regain compliance with and continue to meet the continued listing standards of the Nasdaq Stock Market; the impact of tariffs on Flux Power’s ability to cost-effectively source battery packs and materials used in its products; Flux Power’s ability to obtain raw materials and other supplies for its products at existing or competitive prices and on a timely basis; Flux Power’s anticipated growth strategies and its ability to manage the expansion of its business operations effectively; Flux Power’s ability to maintain or increase its market share in the competitive markets in which it does business; Flux Power’s ability to grow its revenue, increase its gross profit margin and become a profitable business; Flux Power’s ability to fulfill its backlog of open sales orders due to delays in the receipt of key component parts and other potential manufacturing disruptions; Flux Power’s ability to keep up with rapidly changing technologies and evolving industry standards, including its ability to achieve technological advances; Flux Power’s dependence on the growth in demand for its products; Flux Power’s ability to compete with both peers and larger companies with far greater resources than it; Flux Power’s ability to reduce production costs of its product line through new designs, manufacturing and supply arrangements; Flux Power’s ability to shift to new suppliers and incorporate new components into its products in a manner that is not disruptive to its business; Flux Power’s ability to obtain and maintain UL Listings and OEM approvals for its energy storage solutions; Flux Power’s ability to diversify its product offerings and capture new market opportunities; Flux Power’s ability to source its needs for skilled labor, machinery, parts, and raw materials economically; Flux Power’s ability to retain and/or successfully recruit key members of its senior management team; Flux Power’s ability to diversify its customer base to reduce its current dependence on a few major customers; and the expense, timing and outcome of legal proceedings relating to Flux Power’s accounting practices, financial disclosures and employment policies and practices, investigations and information requests that may be initiated or that may be asserted. Actual results could differ from those projected due to numerous factors and uncertainties. Although Flux Power believes that the expectations, opinions, projections, and comments reflected in these forward-looking statements are reasonable, it can give no assurance that such statements will prove to be correct, and that Flux Power’s actual results of ‎operations, financial condition and performance will not differ materially from the ‎results of operations, financial condition and performance reflected or implied by these forward-‎looking statements. Undue reliance should not be placed on the forward-looking statements and investors should refer to the risk factors outlined in Flux Power’s Form 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov/edgar. These forward-looking statements are made as of the date of this release, and Flux Power assumes no obligation to update these statements or the reasons why actual results could differ from those projected, except as required by applicable law.

Flux, Flux Power, and associated logos are trademarks of Flux Power Holdings, Inc. All other third-party brands, products, trademarks, or registered marks are the property of and used to identify the products or services of their respective owners.

Follow us at:
Blog: Flux Power Blog
News Flux Power News
Twitter: @Flux__Power
LinkedIn: Flux Power

Contacts

Media:
media@fluxpower.com
info@fluxpower.com

External Investor Relations:
Leanne Sievers
Shelton Group
flux-ir@sheltongroup.com

VANCOUVER, British Columbia, Oct. 29, 2026 (GLOBE NEWSWIRE) — Lux Metals Corp. (TSXV: LXM) (the “Company” or “Lux”) is pleased to report the copper results for the Zone 32 interval in hole LG26-241, the first hole of its 2026 diamond drill program at the La Grande Gold Project (the “Project”), located in the Eeyou Istchee James Bay region of Québec.

Highlights

• Complete results for the Zone 32 interval (see news release dated October 14, 2026) include 17.57 g/t Au and 0.71% Cu over 19.50 m from 220.5 m downhole (see Figures 1 and 2),
  • including 39.08 g/t Au and 1.45% Cu over 8 m.
  • One sample returned 165 g/t Au and 3.58% Cu over 1m (G240715, 232 to 233m).
  • One sample returned 45.40 g/t Au and 5.79% Cu over 1m (G240717, 233 to 234m).
• The 2026 drill program which comprised 3 holes totalling 1,416 m, has now been completed. Assays for the remaining holes and for the remainder of hole LG26-241 are pending and expected end of November 2026.
• The Company has launched a drone-borne magnetic survey over the Zone 32 area of the Project to map the structures controlling the gold-copper mineralization and refine targets for future drilling.

“With the copper results in hand, LG26-241 shows significant copper alongside the high-grade gold across the Zone 32 interval, confirming the gold-copper character of the system,” said Kim Quyên Nguyên, President and Chief Executive Officer of Lux Metals Corp. “The drill program is now complete, and the magnetic survey will help us trace the structures that control the mineralization as we plan our next steps.“

Figure 1: Drilling Localization Plan with Hole LG26-241

Figure 2: Cross Section of Drilling Location with Hole LG26-241

Table 1: Gold and Copper Assay Results¹ for Hole LG26-241

Hole Number	From (m)	To (m)	Length (m) 2	Au (g/t)	Cu (%)	Au (g/t)3
LG26-241	220.5	240	19.50	17.57	0.71	11.67
Including	229	237	8	39.08	1.45	24.70

¹ Gold values for the Zone 32 interval were previously reported on October 14, 2026. Copper values are reported here for the first time.
² Lengths are reported as core lengths; true width is estimated at 75% of the intercept.
³ Capped gold value at 50 g/t.

Table 2: Drill Hole Collar Information

Hole Number	Easting	Northing	Elevation (m)	Azimuth	Dip	Length (m)
LG26-241	396583	5932335	231	165	50	297

*Coordinate in UTM NAD83, Z18

Hole LG26-241: Copper Results for the Zone 32 Interval

On October 14, 2026, the Company reported gold assays for the Zone 32 interval in hole LG26-241 (17.57 g/t Au over 19.50 m, including 39.08 g/t Au over 8 m). At that time, multi-element (ICP) results, including copper, were pending. These results have now been received (Table 1). Assays for the remainder of hole LG26-241, outside this Zone 32 interval, are pending and will be reported once received and validated.

• Zone 32 (220.5 m to 240.0 m): 0.71% Cu over 19.50 m, including 1.45% Cu over 8 m. One sample returned 165 g/t Au and 3.58% Cu over 1m and another returned 45.40 g/t Au and 5.79% Cu over 1m. Copper is hosted by chalcopyrite, which occurs with pyrite and visible gold in the same sericite-altered shear zones and quartz veins, notably between 232.41 m and 233.62 m, indicating that gold and copper were introduced by the same mineralizing event.

2026 Drill Program Completed

The 2026 diamond drill program at La Grande was completed on October 20, 2026, with 3 holes totalling 1,416 m. In addition to LG26-241, the program tested the eastern extension of Zone 32 and the deep zone identified in historical hole LGS12-224. All core has been logged and sampled, and samples have been delivered to AGAT Laboratories in Val-d’Or. Assay results are expected end of November 2026 and will be released once received and validated.

Magnetic Survey Underway

The Company has started a high-resolution drone-borne magnetic survey over the Zone 32 area of the Project. The survey conducted will cover approximately 160 line-km at 35 m line spacing and is expected to be completed before November 2026.

Zone 32 lies along the contact between the La Grande-Sud tonalite and Yasinski Group volcanic rocks, where gold is concentrated in sheared, sericite-altered and sulphide-bearing tonalite. The survey is designed to map this contact and the associated shear structures at high resolution, identify along-strike and perpendicular structures, and, combined with the 2026 drilling results, help prioritize targets for the next drill program.

Quality Assurance and Quality Control

Drilling was conducted using a diamond drill rig with NQ sized core. Samples were logged and sampled on site, where core was sawn in half and bagged. Quarter core were also sawn for field duplicate. Each bag was secured using a zip-tie, and bagged into a rice bag that was sealed until opening at the laboratory. Samples were transported by road to AGAT Laboratories facility in Val-d’Or, Quebec for standard preparation (code 200075+200087), which include drying at 105°C, crushing 75% passing 2mm, riffle split 250g and pulverize 85% passing 75 microns. A 15g sub-sample is taken and shipped by air to AGAT Laboratory in Calgary for the four acid digestion 48 metals analysis with ICP-OES/MS finish. Most of the pulp is sent to AGAT Laboratory in Thunder Bay for gold fire assay of 50g with AAS finish. Samples returning greater than 10 g/t Au were re-analyzed by fire assay (50 g) with a gravimetric finish. Samples returning greater than 10,000 ppm Cu were re-analyzed for overlimit copper by four acid digestion with ICP OES/MS.

A Quality Assurance / Quality Control (QA/QC) protocol following industry best practice was incorporated to the sampling procedure. Measures include insertion at regular spacing of quartz blank (4%), certified reference materials (4%) and quarter core duplicate (4%). Additional blank material was added after each occurrence of visible gold, and additional high grade gold CRM were added in the mineralized zone. Validation of values for gold and copper from the blank and certified reference material from the release result returned acceptable results from industry standard.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jonathan Marleau, P.Geo., Senior Geologist at Dahrouge Geological Consulting Ltd., an independent consultant of the Company, who is a “qualified person” (within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects) and independent of the Company for purposes of Section 1.5 of National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About Lux Metals Corp.

Lux Metals Corp. (TSXV: LXM) is a Canadian mineral exploration company focused on advancing its flagship La Grande Gold Project in Québec’s James Bay region. The Project hosts the high-grade Zone 32 gold system, supported by extensive historic drilling, direct access via the four-season Trans-Taïga Road, and district-scale exploration potential. For more information, visit www.lux-metals.com.

On Behalf of the Board of Lux Metals Corp.

Kim Quyên Nguyên

President and Chief Executive Officer

For more information, please contact 579-314-0129 or info@lux-metals.com.

Cautionary Note regarding Forward-Looking Statements

This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends”, “expects”, “anticipates”, “plans” or “targeting”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would”, “will”, “potentially” or “likely” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the timing of receipt of remaining assay results from the 2026 drill program; the completion, scope and objectives of the drone-borne magnetic survey; the interpretation of the gold-copper mineralization encountered in hole LG26-241; the identification of additional exploration targets; future drilling activities; and the potential expansion of mineralization at Zone 32 and elsewhere on the Project. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts and are made as of the date of this news release. These forward-looking statements involve numerous risks and uncertainties, including risks related to exploration results; geological interpretation; the continuity and extent of mineralization; the receipt, timing and interpretation of assay results; the results of the magnetic survey; weather and field conditions; the availability of contractors, equipment and personnel; permitting and access; and other risks inherent in mineral exploration, and actual results might differ materially from results suggested in any forward-looking statements. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including that assay results will be received within anticipated timelines; that the magnetic survey will be completed as planned; that exploration activities will proceed as currently contemplated; that contractors, equipment and personnel will remain available; that required permits and access will be obtained and maintained; and that the results of ongoing exploration will support the Company’s geological interpretation and exploration objectives. There can be no assurance that any forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader should not place any undue reliance on forward-looking information or statements. The Company undertakes no obligation to update forward-looking information or statements, other than as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/047eb89d-b359-46cb-b978-f68ebc021eac

https://www.globenewswire.com/NewsRoom/AttachmentNg/9a88bb51-efa0-4bad-b96f-571531393c98

 

• Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain
• One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication
• A one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita

BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy. The findings reinforce the potentially substantial commercial opportunity for investigational Revita and help inform the Company’s ongoing commercial planning.

Fractyl estimates that approximately one million patients each month in the United States face the challenge of weight regain following GLP-1 discontinuation. 65% of those taking a GLP-1 for weight loss (without type 2 diabetes) stop within one year, and only about 1 in 12 people prescribed a GLP-1 for obesity are still on it after three years [1,2]. For patients who stop treatment, the immediate question is how to preserve the weight loss they achieved. Revita is being developed to address this post-GLP-1 weight maintenance need.

The Company’s market research provides meaningful evidence of interest in a procedural treatment option. Among nearly 300 current or recent GLP-1 users surveyed, 33% preferred stopping GLP-1 therapy and receiving a hypothetical procedure. These findings suggest a sizable number of patients are actively interested in alternatives to chronic medications for maintaining weight loss.

“Many patients discontinue GLP-1 therapy due to cost, insurance coverage, side effects, or concerns about long-term medication use. However, growing evidence shows that most patients experience weight gain after discontinuation,” said Dr. Pichamol Jirapinyo, MD, MPH, DABOM, FASGE, FACG, AGAF, Assistant Professor of Medicine at Harvard Medical School and Director of the Bariatric Endoscopy Fellowship at Brigham and Women’s Hospital. “In clinical practice, we are seeing increasing numbers of patients seeking minimally invasive treatment options that could help them discontinue GLP-1 therapy while maintaining their weight loss. There is a substantial unmet need for safe, effective, and durable weight management solutions. A scalable, single-session outpatient procedure that could help patients maintain or achieve additional weight loss after GLP-1 discontinuation would represent a meaningful advancement in obesity care.”

“In addition to the large number of patients already discontinuing GLP-1s who are at immediate risk of weight regain, our research shows that 1 out of 3 patients who are still currently on a GLP-1 would choose a one-time procedural therapy over ongoing medication,” said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health. “This research reinforces our belief that there is meaningful patient interest in a procedural approach to weight maintenance. Together with the encouraging six-month results from REMAIN-1, these findings strengthen our confidence in Revita’s potential to address this need and are helping inform our preparations for future commercialization.”

Addressing a Maintenance Decision Patients Already Face

In the market research, respondents who had discontinued GLP-1 therapy identified the following as their top three reasons for stopping: 1) cost or coverage, 2) concerns about long-term use or safety, and 3) achievement of a weight-loss plateau. 84% selected a one-time procedure as their most valued feature, making it the most frequently selected attribute. Freedom from daily or weekly medication ranked second, selected by 64%. These findings provide further insight into patient priorities and help inform the Company’s planning for potential patient access.

Building on Physician Interest in a One-Time Procedural Alternative

These patient preference results build on Fractyl’s belief that metabolic interventionalists are highly enthusiastic about offering Revita to their patients as an alternative to lifelong GLP-1 therapy. There are approximately 1,000 bariatric and metabolic centers of excellence in the United States, with each center managing an estimated 2,000 patients on GLP-1 therapy today. The patients at these centers represent potential initial candidates for Revita, if authorized. The Company’s planning addresses physician education, treatment-center readiness and potential reimbursement pathways. Additionally, the newly issued Category III CPT code 1122T takes effect on January 1, 2027.

Advancing the Clinical Evidence for Revita

Revita is being evaluated for weight maintenance in adults with obesity following GLP-1 discontinuation. In the REMAIN-1 Pivotal Cohort, participants treated with Revita retained approximately 80% of their GLP-1-induced weight loss on average at six months, meeting the prespecified six-month co-primary endpoint vs sham (p=0.0023).

Revita was generally well tolerated, with no device- or procedure-related serious adverse events reported through the September 24, 2026, interim data cutoff. Fractyl expects to report 12-month topline results from the REMAIN-1 Pivotal Cohort, including the second co-primary endpoint, in the first quarter of 2027.

About Revita

The Revita® DMR System is Fractyl’s lead product candidate, designed to remodel the duodenal lining via a single, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted by chronic metabolic disease. By targeting duodenal dysfunction, Revita is designed to address an underlying driver of obesity and enable durable weight maintenance following GLP-1 discontinuation. Revita has received FDA Breakthrough Device Designation for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom.

About Fractyl Health

Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company’s lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl’s goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact are forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements in this press release include, without limitation, statements regarding: the potential benefits of the Company’s sharpened strategic focus and reprioritization, including the proposed workforce reduction and its anticipated impact on the Company’s expenditures and financial runway; the promise and potential impact of the Company’s clinical trial data and product candidates, including Revita’s potential for maintaining weight loss after GLP-1 based therapy discontinuation and its potential to be the first procedural therapy for post-GLP-1 weight maintenance; the design, initiation, timing and results of clinical studies or readouts, including readouts from the REMAIN-1 Pivotal Cohort, including 12-month data; the potential launch or commercialization of any of the Company’s product candidates or products; the Company’s regulatory strategy, including the timing of any potential De Novo marketing application submission and the potential use and benefits of the De Novo pathway (FDA pre-submission feedback is advisory and non-binding, or as to the timing of any such authorization); the potential treatment population or benefits for any of the Company’s product candidates or products; the Company’s strategic and product development objectives and goals; the Company’s expected quarterly cash burn and cash runway; the Company’s exploration of strategic alternatives for Rejuva and the potential benefits thereof; and the timing of any of the foregoing.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in its filings with the Securities and Exchange Commission (the SEC), including the “Risk Factors” section of its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents it subsequently files with or furnishes to the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 10, 2026.

These forward-looking statements are based on management’s current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

1. Rodriguez PJ, et al. JAMA Netw Open. 2025;8(1):e2457349. jamanetwork.com
2. Prime Therapeutics, three-year GLP-1 persistence analysis, June 25, 2025 (commercial claims, n=5,780, 60-day gap). primetherapeutics.com

Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results

IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027

KRAS Wild-Type Subgroup Achieved 43.3% ORR Versus 11.4% in KRAS-Mutant Disease and Novel Biomarker-Enriched Subgroup Achieved 59.1% ORR

POSITILITY, a First-In-Class Biomarker-Enriched Study with Registrational Intent, to Begin Enrollment in November 2026

PHILADELPHIA, Oct. 29, 2026 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company developing and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer, today announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial and a first-in-class biomarker-enriched precision TIL strategy for lifileucel in previously treated non-squamous mNSCLC.

IOV-LUN-202 Cohorts 1 and 2 are completing enrollment and support the planned sBLA for lifileucel in non-squamous mNSCLC in 2027.

As of the October 14, 2026 data cutoff, 17 of 69 patients responded, representing an ORR of 24.6%, consistent with the 25.6% ORR previously reported in 39 patients.

A retrospective analysis identified a biomarker-enriched subgroup defined by Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type status, human epidermal growth factor receptor 2 (HER2) wild-type status, and current or former smoking. This subgroup represented less than one-third of the broader study population (22 of 69 patients) but accounted for more than three-quarters of the observed responses (13 of 17), with an ORR of 59.1% (13 of 22 patients).

The KRAS findings and further biomarker enrichment provide the clinical foundation for Iovance’s precision TIL strategy. Iovance will prospectively evaluate this novel approach with POSITILITY, a first-in-class, prospective, biomarker-enriched cohort within the Phase 2 IOV-LUN-202 trial, designed with registrational intent.

Updated Results in the Broader Non-Squamous mNSCLC Population

Updated results from Cohorts 1 and 2 include 30 additional patients, bringing the total to 69 patients with non-squamous mNSCLC whose disease had progressed on or after platinum-based chemotherapy and immune checkpoint inhibitor therapy. Patients were enrolled without prospective selection using the novel biomarker-enrichment criteria.

The 17 reported responses included 15 confirmed responses and two unconfirmed partial responses (uPRs) awaiting confirmation. Radiologic assessments by an independent review committee are ongoing.

Response durability and the safety profile remained consistent with previous reports. The study incorporates an updated, reduced-dose lymphodepletion regimen that has improved the overall safety profile.

The broader IOV-LUN-202 Cohorts 1 and 2 are completing enrollment, with approximately 80 non-squamous NSCLC patients expected in the final dataset, and an sBLA for lifileucel in non-squamous mNSCLC is planned for 2027. Discussions with the U.S. Food and Drug Administration (FDA) are ongoing, and Iovance expects to provide further updates on the broader-population program in 2027.

KRAS Wild-Type Status Anchors the Precision TIL Strategy

To understand differences in response, Iovance evaluated clinical outcomes alongside tumor genomic and translational data. The analysis focused on tumor antigen presentation—the process by which tumor cells display targets for recognition by polyclonal TIL—and immune activity within the tumor microenvironment. Published preclinical studies in lung cancer models have linked oncogenic KRAS signaling to impaired antigen presentation and immune suppression, providing a biological rationale for investigating the association between KRAS status and response to lifileucel.¹

KRAS status emerged as the lead biomarker for Iovance’s novel enrichment strategy. In the broader population of 69 patients with non-squamous mNSCLC, the ORR was 43.3% (13 of 30 patients) in the KRAS wild-type subgroup, compared with 11.4% (4 of 35 patients) in the KRAS-mutant subgroup. Both complete responses occurred in patients with KRAS wild-type tumors. These findings provided the rationale for further enrichment within the KRAS wild-type subgroup.

Building on this signal, Iovance incorporated HER2 wild-type status and current or former smoking status into its enrichment strategy. These criteria draw on standard tumor genomic testing and routinely collected smoking history. Preclinical research suggests that aberrant HER2 signaling can suppress antitumor immunity, while smoking-associated mutations generate additional tumor targets for recognition by polyclonal TIL.

All 13 responses in the KRAS wild-type subgroup occurred among the 22 patients meeting the combined enrichment criteria, yielding an ORR of 59.1%, including both complete responses. These patients represented 31.9% of the broader study population but accounted for 76.5% of the observed responses. Together, the clinical findings and biological rationale support prospective evaluation of this combined enrichment strategy for lifileucel. The results for these populations are summarized in the following table.

Population	n	ORR*
Broader non-squamous NSCLC population	69	24.6% (17/69)
KRAS wild-type	30	43.3% (13/30)
KRAS-mutant	35	11.4% (4/35)
KRAS wild-type + HER2 wild-type	25	52.0% (13/25)
KRAS wild-type + HER2 wild-type + ever smoker	22	59.1% (13/22)

*ORRs include two uPRs, pending confirmation: one in the KRAS wild-type group and one in the KRAS-mutant group. Four KRAS-unassessed patients are excluded.

“These findings are reshaping how we develop TIL therapy for mNSCLC,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance. “The expanded dataset reinforces the activity of lifileucel in previously treated disease, while the concentration of responses in KRAS wild-type tumors points to a more precision approach to patient selection. In the enriched subgroup, nearly six in ten patients responded, including two complete responses. We believe these insights could expand lifileucel’s potential as a one-time treatment for mNSCLC, with a best-in-class profile compared to other therapies in development.”

Iovance has launched POSITILITY as a first-in-class, prospective, biomarker-enriched cohort within the ongoing IOV-LUN-202 program, with enrollment to begin in November 2026 at the first of over 70 existing IOV-LUN-202 sites. Iovance intends for the study to support a potential registrational pathway, subject to FDA feedback.

“Tumor-reactive T cells need recognizable targets and a tumor microenvironment that supports a sustained antitumor response,” said Wayne Rothbaum, co-Chair of the Scientific Committee of Iovance’s Board of Directors. “The response pattern in IOV-LUN-202 provided a clinical rationale for testing how tumor biology can guide TIL therapy. Starting with KRAS status, and refining selection through HER2 status and smoking history, we identified a highly responsive mNSCLC subgroup where TIL biology converges with an immuno-reactive tumor microenvironment. We now aim to translate these novel findings into a precision development plan utilizing KRAS-based stratification, designed to identify patients most likely to benefit from lifileucel therapy.”

Supporting Frontline Data and Development Plans

In a separate analysis of frontline Cohort 3A of IOV-COM-202, six of seven patients with non-squamous mNSCLC, KRAS wild-type tumors, and a current or former smoking history responded to lifileucel plus pembrolizumab (without chemotherapy), yielding an ORR of 85.7%. HER2 status was not assessed in these patients. These findings provide additional rationale for prospective evaluation of lifileucel in the frontline setting.

Iovance plans to initiate OPTILISM, an innovative, frontline trial in biomarker-enriched non-squamous mNSCLC, in 2027. OPTILISM and the second-line POSITILITY trial are intended to evaluate lifileucel across two treatment settings and assess the role of biomarker-guided patient selection within the mNSCLC development program.

Across the patient populations enrolling into OPTILISM and POSITILITY, the prevalence of the biomarker-enriched population is estimated at approximately 45% of the cases of non-squamous mNSCLC diagnosed each year in the U.S., leading to more than 90,000 annual deaths and representing a significant market opportunity for lifileucel.

Additional details on the clinical results and development plans are available in a presentation posted to the Investor Relations section of www.iovance.com.

About IOV-LUN-202

IOV-LUN-202 is a Phase 2 study evaluating lifileucel in patients with previously treated mNSCLC. This update reports results from the 69 patients in Cohorts 1 and 2 with non-squamous histology who received a total viable cell count of at least 10 billion. Lifileucel remains investigational for the treatment of mNSCLC.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Iovance owns patent rights and other intellectual property rights related to the biomarker-directed strategy described in this press release. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

References

1. Mugarza E, et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Science Advances. 2022;8:eabm8780. https://doi.org/10.1126/sciadv.abm8780

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements.

Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the size of the addressable patient populations for, and the acceptance by the market of, our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our iCTC facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial supply or clinical supply; the risks related to our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates, including our biomarker-directed strategy; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates and any required companion diagnostics; whether clinical trial results from our clinical studies and cohorts, and meetings with regulatory authorities, may support registrational studies, including biomarker-selected studies such as POSITILITY, and subsequent approvals by regulatory authorities, and the risk that our clinical trials, including registrational trials, may experience delays in site activation, enrollment, or data readouts, may not meet their primary endpoints, or may not support approval; clinical results, whether preliminary, interim, or final, which may include efficacy and safety results, from clinical trials or cohorts, including retrospective subgroup analyses, may not be confirmed or reflected in independent review assessments or the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior or future trials or cohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials, including comparisons to other therapies, or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities or others; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

• Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026
• Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026
• Generated positive operating cash flow for the second consecutive quarter
• Reaffirmed full-year 2026 financial guidance
• Conference call and webcast today, October 29, 2026, at 8:00 a.m. EDT

FLORHAM PARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter,” said Steve Basta, President and Chief Executive Officer of Phathom. “We continue to grow VOQUEZNA prescribing depth among GI providers and have implemented several initiatives designed to make it easier for physicians to prescribe and patients to obtain our first-in-class GERD treatment. These efforts build on our commercial momentum, which includes recently reaching the milestone of two million VOQUEZNA prescriptions filled.”

“Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter,” said Sanjeev Narula, Chief Financial and Business Officer of Phathom. “We have established a stronger financial foundation through continued revenue growth and disciplined expense management, while maintaining the flexibility to invest in our commercial and clinical development priorities. We remain confident in our ability to meet our financial obligations and deliver on our full-year 2026 guidance.”

Recent Business Highlights and Third Quarter 2026 Results

VOQUEZNA Commercial Progress:

• Over 2 million total VOQUEZNA prescriptions have been filled since launch through October 16, 2026. After achieving the first million prescriptions just over two years into launch, Phathom reached its second million filled prescriptions less than a year later.
• Approximately 380,000 total VOQUEZNA prescriptions were filled during the third quarter 2026, including approximately 248,000 covered prescriptions and 132,000 cash-pay prescriptions.
• Covered prescriptions in the third quarter amounted to approximately 65% of total quarterly prescriptions. Covered prescription volume increased approximately 19% compared to the second quarter 2026. Cash-pay prescription volume increased approximately 6% sequentially.
• Phathom implemented several initiatives designed to improve VOQUEZNA access dynamics, including its “Access First” field messaging and promotional materials, and at the end of the third quarter, the introduction of a new copay offering through Phathom’s pharmacy partner, BlinkRx, under which eligible commercially insured patients may pay as little as $0 for VOQUEZNA.

Clinical and Regulatory Updates:

• VOQUEZNA Phase 3 As-Needed Program
  • Building on previously reported positive Phase 2 results, on September 29, 2026, Phathom announced the initiation of pHalcon-NERD-302, a registrational Phase 3 study of VOQUEZNA for as-needed (PRN) use in Non-Erosive Gastroesophageal Reflux Disease (NERD). The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028.
  • If successful, this Phase 3 program could support a potential label expansion for VOQUEZNA, which, if approved, could offer a differentiated treatment option and potentially expand the market opportunity for VOQUEZNA, by providing flexibility for patients with NERD to take treatment as-needed instead of chronic daily dosing.
• Eosinophilic Esophagitis (EoE)
  • Phathom expects to report topline results during the fourth quarter 2026 for the 12-week blinded treatment portion of its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with Eosinophilic Esophagitis (EoE).

• VOQUEZNA Data at ACG 2026
  • At the American College of Gastroenterology’s (ACG) 2026 Annual Scientific Meeting, Phathom presented new data highlighting the clinical and potential economic value of VOQUEZNA in GERD. A new predictive cost-effectiveness analysis projected VOQUEZNA to be cost-effective compared with proton pump inhibitors (PPIs) for the healing and maintenance of Erosive GERD in adults, with potential healthcare cost savings at the estimated net price based on clinical healing outcomes and fewer anticipated downstream interventions required.
  • Vonoprazan, the active drug in VOQUEZNA, was also the subject of 38 independent, investigator-initiated abstracts presented at ACG 2026, reflecting continued scientific interest across GERD, H. pylori eradication, and other gastrointestinal conditions.
• VOQUEZNA Regulatory Exclusivity
  
  • On October 26, 2026, the U.S. District Court for the District of Columbia granted Phathom’s motion to intervene in the litigation filed by BDR Pharmaceuticals against the FDA regarding VOQUEZNA’s regulatory exclusivity. On October 23, 2026, FDA opened a public comment docket on issues raised in the litigation, with comments due November 23, 2026.
  • Phathom believes the FDA carefully and correctly evaluated this issue in its June 6, 2025 decision granting Phathom’s December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032, as reflected in the Orange Book. Phathom intends to vigorously defend its statutory exclusivities.

Third Quarter 2026 Financial Results:

• Revenue: Net revenues for the third quarter 2026 were $84.7 million, an increase of $35.2 million compared to $49.5 million for third quarter 2025. The increase was due to continued growth from execution of Phathom’s commercial strategy.
• Research and development (R&D) expenses: R&D expenses for the third quarter 2026 were $8.7 million, an increase of $1.7 million compared to $7.0 million for third quarter 2025. The increase was primarily due to higher clinical development and regulatory costs.
• Selling, general and administrative (SG&A) expenses: SG&A expenses for the third quarter 2026 were $57.7 million, an increase of $6.1 million compared to $51.6 million for third quarter 2025. The increase was primarily due to higher promotional and personnel-related expenses.
• Operating expenses: Operating expenses for the third quarter 2026 were $66.4 million, compared to $58.6 million for third quarter 2025. The increase was primarily attributable to higher clinical development costs associated with Phathom’s ongoing and planned clinical programs, as well as increased commercial investment supporting its sales force and Access First initiatives. Third quarter 2026 operating expenses included non-cash stock-based compensation of $5.9 million, compared to $9.3 million in the prior-year period. Non-GAAP operating expenses, excluding stock-based compensation, were $60.5 million, compared to $49.3 million for third quarter 2025.
• Net loss: Net loss for the third quarter 2026 was $13.9 million, compared to $30.0 million for third quarter 2025. Non-GAAP adjusted net income for the third quarter 2026 was $3.0 million compared to a non-GAAP adjusted net loss of $11.2 million for the same period in 2025. These non-GAAP adjusted amounts, as more fully described below under “Non-GAAP Financial Measures,” exclude non-cash stock-based compensation charges, non-cash interest expense related to the accounting for our revenue interest financing liability, which is in excess of the actual interest owed, and interest expense related to the amortization of debt discount on our term loan. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
• Cash and cash equivalents: As of September 30, 2026, cash and cash equivalents were $184.6 million, an increase of $2.1 million compared to the second quarter ended June 30, 2026. Phathom continues to believe cash on hand along with anticipated future cash generated from operations will be sufficient to invest in its business and satisfy all outstanding debt obligations without requiring additional debt or equity financing.

2026 Financial Guidance
Phathom is maintaining its full-year 2026 financial guidance as follows:

		FY 2026 Guidance
	Net revenue	$310–325 million
	Gross-to-net discount	55–59%
	Gross margin	~80%
	Non-GAAP operating expenses, excluding stock-based compensation	$235–245 million

Conference Call and Webcast
Phathom will host a conference call and webcast to discuss its third quarter 2026 financial results and business highlights today, October 29, 2026, at 8:00 a.m. EDT. A live webcast will be available on the investors page of Phathom’s website under Events & Presentations. A replay of the webcast will be available following completion of the call and will be archived for up to 90 days.

Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Phathom has provided non-GAAP operating profitability, operating expense, adjusted net loss and adjusted net loss per share, adjusted to exclude the items below. Non-GAAP financial measures are not an alternative to financial measures prepared in accordance with GAAP. However, Phathom believes the presentation of non-GAAP operating profitability, adjusted operating expense, net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance. Non-GAAP operating profitability and non-GAAP operating expense exclude non-cash stock-based compensation, which is impacted by changes in the market price of common stock. Adjusted net loss and net loss per share exclude (i) non-cash stock-based compensation, (ii) interest expense related to the accounting for our revenue interest financing liability, which is in excess of the actual interest owed, and (iii) interest expense related to the amortization of debt discount on our term loan. Phathom does not provide a reconciliation of projected non-GAAP operating profitability or operating expense to GAAP operating expense due to the inherent difficulty in forecasting and quantifying non-cash stock-based compensation which is dependent on changes in the market price of common stock and necessary for such reconciliation.

Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom’s results of operations. When GAAP financial measures are viewed in conjunction with these non-GAAP financial measures, investors are provided with a more meaningful understanding of Phathom’s ongoing operating performance and are better able to compare Phathom’s performance between periods. In addition, these non-GAAP financial measures are among those indicators Phathom uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this press release.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: our guidance and expectations regarding financial results for 2026, including revenues from sales of VOQUEZNA, operating expenses, gross-to-net and gross margin; our beliefs, outlook and expectations with respect to future commercialization plans, activities and potential results; our belief in the potential size of the commercial opportunity for VOQUEZNA and ability to realize its potential; our belief in the sufficiency of our cash and expected revenues to fund our current operating plan and meet outstanding financial obligations; our development plans and potential timelines including our expectations for reporting topline results from the pHalcon-EoE-201 trial and our Phase 3 clinical trial in NERD as-needed use; our belief that the FDA correctly evaluated and recognized the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets; our intent to take appropriate actions to protect our statutory exclusivities; the expected duration of NCE exclusivity for VOQUEZNA tablets; the potential timing and outcome of the litigation filed by BDR and the second purported ANDA filer; the timing and potential impact of the FDA public docket and potential decisions the FDA may make in light of the comments received; our business strategy, goals, mission and vision, including our goal to be a leader in GI; and our other expectations, forecasts and predictions as to future performance, financial and other results and likelihood of success. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: we may not be able to continue to successfully commercialize VOQUEZNA, achieve operating results, revenues or growth at the levels we expect, or realize the potential market opportunity; the market opportunity for VOQUEZNA may be significantly smaller than our expectations; market acceptance for VOQUEZNA from healthcare professionals, patients, and payors in the indications for which it is approved may be significantly lower than we anticipate; we may encounter coverage, reimbursement, market access, or other issues in the course of our commercialization efforts that may negatively impact our efforts and results; our ongoing and planned commercial activities may not have the impact on results we expect; the unmet need for new treatment options in GERD may not be as high as we anticipate; estimates of the number of patients with the disorders for which VOQUEZNA is approved, now or in the future, and our estimates of potential market size may not be accurate; our decisions as to where to allocate our resources and focus our efforts may not lead to the results we expect; BDR and the second purported ANDA filer may succeed in challenging the FDA’s recognition of the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets, which would result in a reduction in the period of regulatory exclusivity and permit the FDA to receive and potentially approve ANDAs referencing VOQUEZNA tablets earlier than currently anticipated; members of the public may comment on the FDA public docket in a manner adverse to our position, which may influence the FDA’s decision, and the FDA may, in light of those comments or otherwise, reconsider, modify or reverse its prior decision recognizing the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets; the litigation, including any appeals, may be lengthy, costly and distracting to management, and its timing and outcome are uncertain; developments in the litigation or related to the FDA’s request for comments, or public perception of them, may hurt our stock price, VOQUEZNA sales, business, financial condition and prospects; we may be unsuccessful in defending our Orange Book-listed patents against challenges by third parties; we may face competition earlier than expected if we lose regulatory or patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets, including as a result of an adverse outcome in the BDR and related litigation or an adverse FDA decision; our results may be negatively impacted by the launch of other competitive products; we may experience adverse impact as the result of our dependence on third parties in connection with commercialization, product manufacturing, research and preclinical and clinical testing; we may be negatively impacted by regulatory developments or other governmental actions in the United States, including government healthcare reform; we may encounter unexpected adverse side effects or inadequate efficacy of VOQUEZNA that may limit or impair market acceptance or impair current or future development or regulatory approvals, or may result in recalls, withdrawals or product liability claims; we may not be able to obtain and maintain intellectual property protection important to our business; if we were to breach our license agreement with Takeda for vonoprazan, Takeda might take action, including termination, that would significantly impair our business; we may encounter potential delays in the commencement, recruitment, enrollment, data readouts and completion of our clinical trials; we may receive negative or mixed results from our ongoing or future clinical trials that impact our business, goals or future opportunities; our operating expenses and cash use may be higher than we anticipate, including if we decide to engage in activities not currently in our plan or if we face unexpected, or higher than anticipated, expenses, including as the result of unexpected events such as litigation; depending on our operating results and activities, we may not achieve our financial guidance and we may not maintain operating profitability or cash flow positivity on the timelines we expect or at all; for the foregoing or other reasons, in the future, we may not have sufficient cash to fund our operations at the levels we expect or to meet our obligations under the term debt or revenue interest financing agreement (RIFA) or our other obligations or to enable us to achieve profit from operations; we may need to or decide to raise additional capital and we may not be able to do so on acceptable terms or at all; and any of the foregoing or other factors may negatively impact our ability to achieve our plans, goals, mission, vision and potential. For additional discussion of these and other risks, see the risk disclosure in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

Selected Condensed Balance Sheets
(in thousands)
(unaudited)
		September 30, 2026				December 31, 2025
Cash and cash equivalents		$	184,558			$	129,972
Total assets		$	345,020			$	259,149
Total liabilities		$	692,659			$	697,318
Total stockholders’ deficit		$	(347,639	)		$	(438,169	)
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Product revenue, net		$	84,722			$	49,504			$	217,297			$	117,526
Cost of revenue			18,367				6,190				45,458				14,951
Gross profit			66,355				43,314				171,839				102,575
Operating expenses:
Research and development			8,745				7,027				24,330				25,287
Selling, general and administrative			57,695				51,558				167,037				231,346
Total operating expenses			66,440				58,585				191,367				256,633
Loss from operations			(85	)			(15,271	)			(19,528	)			(154,058	)
Other (expense) income:
Interest income			1,600				1,413				4,846				5,840
Interest expense			(15,387	)			(16,108	)			(46,287	)			(51,696	)
Other expense, net			(25	)			(7	)			(879	)			(185	)
Total other expense			(13,812	)			(14,702	)			(42,320	)			(46,041	)
Net loss and comprehensive loss		$	(13,897	)		$	(29,973	)		$	(61,848	)		$	(200,099	)
Net loss per share, basic and diluted		$	(0.16	)		$	(0.41	)		$	(0.74	)		$	(2.76	)
Weighted-average shares of common stock outstanding, basic and diluted			84,892,631				73,396,435				83,573,861				72,615,910
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except share and per share amounts)
(unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Reconciliation of GAAP to Non-GAAP adjusted net income (loss):
GAAP net loss		$	(13,897	)		$	(29,973	)		$	(61,848	)		$	(200,099	)
Stock-based compensation expense (A)			5,921				9,297				18,167				23,109
Non-cash interest on revenue interest financing liability			10,009				8,749				29,138				30,058
Interest expense related to amortization of debt discount			953				775				2,709				2,205
Non-GAAP adjusted net income (loss)		$	2,986			$	(11,152	)		$	(11,834	)		$	(144,727	)
Reconciliation of GAAP to Non-GAAP adjusted net income (loss) per share — basic and diluted:
GAAP net loss per share — basic and diluted		$	(0.16	)		$	(0.41	)		$	(0.74	)		$	(2.76	)
Stock-based compensation expense (A)			0.07				0.13				0.22				0.32
Non-cash interest on revenue interest financing liability			0.12				0.12				0.35				0.41
Interest expense related to amortization of debt discount			0.01				0.01				0.03				0.03
Non-GAAP net income (loss) per share — basic and diluted		$	0.04			$	(0.15	)		$	(0.14	)		$	(2.00	)
Weighted-average shares of common stock outstanding, basic and diluted			84,892,631				73,396,435				83,573,861				72,615,910
(A) Stock-based compensation consists of the following:
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Research and development			828				2,063				2,753				5,043
Selling, general and administrative			5,093				7,234				15,414				18,066

FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3^rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here).

Inducement Grant

In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 63,600 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on October 28, 2026 to the newly hired employees.

The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to the acceptance of employment with Sagimet.

The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on October 28, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee’s employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to each individual’s continued service with Sagimet through the applicable vesting dates.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company advancing a portfolio of novel fatty acid synthase (FASN) inhibitors. FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can cause elevated sebum and inflammation. FASN is also implicated in other diseases, including MASH and certain FASN-dependent tumor types. Denifanstat, Sagimet’s lead drug candidate, is an oral, once-daily FASN inhibitor currently being evaluated in a U.S. Phase 3 registrational clinical trial for moderate to severe acne. For more information, visit www.sagimet.com.

Investor Contact:
Joyce Allaire 
LifeSci Advisors 
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

TEL AVIV, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, today announced that management will be participating in the following investor conferences.

• 7th Annual Needham Virtual Tech Week — November 18^th, 2026, Virtual.
• 30th Annual UBS Global Technology and AI Conference — December 1^st, 2026, Scottsdale, AZ.
• 29th Annual Needham Growth Conference — January 12^th, 2027, New York, NY.

If interested in meeting with Radware management, please contact your sales representative at each respective investment bank or contact the Company directly at ir@radware.com.

About Radware
Radware® (NASDAQ: RDWR) is a global leader in application security and delivery solutions for multi-cloud environments. The company’s cloud application, infrastructure, API, and AI security solutions use AI-driven algorithms for precise, behavior-based, real-time protection against sophisticated web, application, and DDoS attacks, API abuse, business logic threats, and malicious bots. Radware delivers end-to-end API security, including discovery, posture management, testing, and runtime protection, along with advanced protection for AI agents and models. Enterprises and carriers worldwide rely on Radware to address evolving cyberthreats, protect their brands and business operations, and reduce costs. For more information, please visit the Radware website.

Radware encourages you to join our community and follow us on Facebook, LinkedIn, Radware Blog, X, and YouTube.

©2026 Radware Ltd. All rights reserved. Any Radware products and solutions mentioned in this press release are protected by trademarks, patents, and pending patent applications of Radware in the U.S. and other countries. For more details, please see: https://www.radware.com/LegalNotice/. All other trademarks and names are property of their respective owners.

Radware believes the information in this document is accurate in all material respects as of its publication date. However, the information is provided without any express, statutory, or implied warranties and is subject to change without notice.

The contents of any website or hyperlinks mentioned in this press release are for informational purposes only and the contents thereof are not part of or incorporated by reference into this press release.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. securities laws. Any forward-looking statements made herein that are not statements of historical fact, including statements about Radware’s plans, objectives, expectations, beliefs, projections, future financial performance, business strategies, market opportunities, and developments in our industry, are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “forecast,” “target,” and similar expressions, as well as future or conditional verbs such as “will,” “should,” “would,” “may,” and “could.”

Because such statements deal with future events, they are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impact of global market and economic conditions; our dependence on independent distributors; disruptions in our supply chain, including shortages of components or manufacturing capacity; our reliance on a limited number of vendors; our ability to attract, train and retain qualified personnel; intense competition in the cybersecurity and application delivery markets; our ability to develop new solutions and enhance existing solutions; risks related to defects, vulnerabilities or failures in our products or services, including cybersecurity incidents affecting our systems or those of our customers; risks associated with the use of artificial intelligence technologies, including evolving regulatory frameworks, litigation exposure and reputational considerations; risks related to our information technology systems, including failures, disruptions or security breaches; outages, interruptions, or delays in hosting or cloud-based services; risks related to the interoperability of our products; risks associated with our global operations; and geopolitical risks, including instability in the Middle East and Israel.

These factors are not exhaustive. For a more detailed description of the risks and uncertainties affecting Radware, please refer to Radware’s Annual Report on Form 20-F and other reports filed with or furnished to the Securities and Exchange Commission (SEC) from time to time.

Forward-looking statements speak only as of the date on which they are made, and, except as required by applicable law, Radware undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of such statements. Radware’s public filings are available from the SEC’s website at www.sec.gov or on Radware’s website at www.radware.com.

CONTACTS
Investor Relations:
Yisca Erez, +972-72-3917211, ir@radware.com

Media Contact:
Gina Sorice, ginaso@radware.com

TORONTO, Oct. 29, 2026 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX:TSK | OTCQX:TSKFF) is pleased to announce results from an additional 17 drill holes from the Bralorne West Zone – 2026 Bralorne Gold Project resource conversion program, following the previously reported first 75 drill holes, predominantly targeting dip and strike extensions in the major ore veins at its currently producing Mustang Mine.

Highlights from the additional 17 drill holes include:

• SB-2026-032 – 40.90 g/t Au over 0.70 m within 16.29 g/t Au over 2.15 m on the 101 Vein
• SB-2026-035 – 56.96 g/t Au over 0.80 m within 19.84 g/t Au over 2.30 m on the 55HW Vein
• SB-2026-037 – 58.36 g/t Au over 0.50 m within 12.78 g/t Au over 2.45 m on the 101 Vein
• SB-2026-037 – 33.44 g/t Au over 0.55 m within 9.74 g/t Au over 3.05 m on the 55 Vein
• SB-2026-038 – 32.07 g/t Au over 0.60 m within 8.77 g/t Au over 2.20 m on the 55HW Vein
• UB-2026-046 – 23.78 g/t Au over 1.05 m within 11.10 g/t Au over 2.25 m on the 55HW Vein
• UB-2026-048 – 20.26 g/t Au over 0.60 m within 5.62 g/t Au over 2.25 m on the 276 Vein
• UB-2026-050 – 25.20 g/t Au over 0.55 m within 7.75 g/t Au over 2.10 m on the 55HW Vein
• UB-2026-050 – 15.76 g/t Au over 0.65 m within 9.51 g/t Au over 2.45 m on the 276 Vein
• UB-2026-052 – 38.63 g/t Au over 0.85 m within 15.14 g/t Au over 2.20 m on the 55HW Vein
• UB-2026-054 – 32.46 g/t Au over 0.60 m within 11.25 g/t Au over 2.00 m on the 278 Vein
• UB-2026-058 – 11.90 g/t Au over 0.50 m within 5.72 g/t Au over 2.40 m on the 55HW Vein
• UB-2026-060 – 30.19 g/t Au over 0.55 m within 12.34 g/t Au over 2.45 m on the 55HW Vein
• UB-2026-060 – 301.88 g/t Au over 0.55 m within 79.23 g/t Au over 2.10 m on the 276 Vein

Up to and including data in this news release, the total drilling at the Mustang Mine in 2026 is 25,442 m in 92 drill holes. The resource conversion drill program is focused on infill drilling of the Alhambra, BK, and BK-9870 veins and Bralorne West’s 101, 55 HW, 276, and 55 veins, all within the Mustang Mine. This release highlights results from the Bralorne West zone.

Underground mine development continues to advance in the Bralorne West zone, where the first underground diamond drill bay is now actively infilling the zone. Initial drilling has returned encouraging results, with gold grades exceeding expectations while demonstrating consistent mineralized widths and grade continuity.

Kyle Orr, Talisker’s Vice President, Exploration, commented: “We are excited by the initial results from underground drilling in the Bralorne West zone. As underground development advances and drilling continues to expand our understanding of the zone, these results are providing valuable insight into the continuity of mineralization and reinforcing the significant growth potential within the Bralorne Gold Project.”

All drill holes in this release are located in the Mustang Mine and hosted in diorite and/or intermediate to felsic dyke. Major vein structures intersected are orogenic quartz-carbonate veins with banded sulfide septae. Crack-seal septae host fine-grained arsenopyrite and pyrite mineralization. Alteration halos consist of strong silica – sericite ± mariposite alteration with disseminated sulfides.

Bralorne Gold Project – 2026 Diamond Drilling Top Intercepts Table
Drill Hole Name	From (m)	To (m)	Interval (m)	Au (g/t)	Interpreted Structure
SB-2026-032	44.45	45.00	0.55	0.28	Vein Halo
SB-2026-032	45.00	46.05	1.05	1.72	Vein Halo
SB-2026-032	46.05	46.55	0.50	5.24	Untargeted Vein
SB-2026-032	299.60	300.20	0.60	6.13	Untargeted Vein
SB-2026-032	300.20	301.00	0.80	0.53	Vein Halo
SB-2026-032	301.00	301.60	0.60	0.03	Vein Halo
SB-2026-032	327.00	327.65	0.65	0.01	Vein Halo
SB-2026-032	327.65	328.30	0.65	12.50	Untargeted Vein
SB-2026-032	328.30	329.00	0.70	0.01	Vein Halo
SB-2026-032	348.45	349.40	0.95	6.72	Vein Halo
SB-2026-032	349.40	349.90	0.50	0.04	Vein Halo
SB-2026-032	349.90	350.60	0.70	40.90	101 Vein
SB-2026-032	401.25	402.00	0.75	13.40	55HW Vein
SB-2026-032	402.00	402.50	0.50	4.39	55HW Vein
SB-2026-032	402.50	403.00	0.50	3.11	55HW Vein
SB-2026-032	403.00	403.90	0.90	2.89	55HW Vein
SB-2026-033	340.05	340.55	0.50	0.86	Untargeted Vein
SB-2026-033	340.55	341.20	0.65	0.49	Vein Halo
SB-2026-033	341.20	341.80	0.60	2.39	Vein Halo
SB-2026-033	341.80	342.40	0.60	11.71	101 Vein
SB-2026-034	267.00	267.80	0.80	3.45	Vein Halo
SB-2026-034	267.80	268.45	0.65	2.08	Vein Halo
SB-2026-034	268.45	268.95	0.50	2.75	Vein Halo
SB-2026-034	268.95	269.45	0.50	5.41	Untargeted Vein
SB-2026-034	329.80	330.30	0.50	1.30	Vein Halo
SB-2026-034	330.30	330.80	0.50	7.97	55HW Vein
SB-2026-034	330.80	331.30	0.50	1.02	55HW Vein
SB-2026-034	331.30	331.80	0.50	15.07	55HW Vein
SB-2026-035	257.55	258.20	0.65	18.43	101 Vein
SB-2026-035	258.20	258.70	0.50	0.53	Vein Halo
SB-2026-035	258.70	259.70	1.00	0.31	Vein Halo
SB-2026-035	309.55	310.35	0.80	56.96	55HW Vein
SB-2026-035	310.35	310.85	0.50	0.11	Vein Halo
SB-2026-035	310.85	311.85	1.00	0.01	Vein Halo
SB-2026-036	366.00	366.80	0.80	4.72	55 Splay
SB-2026-036	366.80	367.45	0.65	8.05	55 Splay
SB-2026-036	367.45	368.05	0.60	2.15	55 Splay
SB-2026-036	374.35	375.10	0.75	2.52	Vein Halo
SB-2026-036	375.10	376.10	1.00	3.27	55 Vein
SB-2026-036	376.10	376.75	0.65	7.07	55 Vein
SB-2026-037	262.50	263.00	0.50	1.58	Vein Halo
SB-2026-037	263.00	263.50	0.50	58.36	101 Vein
SB-2026-037	263.50	264.00	0.50	0.27	Vein Halo
SB-2026-037	264.00	264.95	0.95	1.27	Vein Halo
SB-2026-037	331.90	332.50	0.60	3.08	55HW Vein
SB-2026-037	332.50	333.00	0.50	14.03	55HW Vein
SB-2026-037	333.00	333.50	0.50	1.24	Vein Halo
SB-2026-037	333.50	334.00	0.50	1.41	Vein Halo
SB-2026-037	358.40	359.05	0.65	4.49	Vein Halo
SB-2026-037	359.05	359.55	0.50	5.96	Vein Halo
SB-2026-037	359.55	360.10	0.55	33.44	55 Vein
SB-2026-037	360.10	360.90	0.80	3.31	55 Vein
SB-2026-037	360.90	361.45	0.55	5.01	55 Vein
SB-2026-038	249.00	250.00	1.00	0.92	Vein Halo
SB-2026-038	250.00	250.55	0.55	2.41	Vein Halo
SB-2026-038	250.55	251.05	0.50	7.66	101 Vein
SB-2026-038	280.50	281.00	0.50	0.18	Vein Halo
SB-2026-038	281.00	281.90	0.90	5.14	278 Vein
SB-2026-038	281.90	282.50	0.60	0.01	Vein Halo
SB-2026-038	312.80	313.40	0.60	32.07	55HW Vein
SB-2026-038	313.40	313.90	0.50	0.09	Vein Halo
SB-2026-038	313.90	315.00	1.10	0.01	Vein Halo
UB-2026-046	53.90	54.60	0.70	0.85	Vein Halo
UB-2026-046	54.60	55.50	0.90	5.56	101 Vein
UB-2026-046	55.50	56.05	0.55	0.01	Vein Halo
UB-2026-046	123.85	124.55	0.70	0.01	Vein Halo
UB-2026-046	124.55	125.05	0.50	0.01	Vein Halo
UB-2026-046	125.05	126.10	1.05	23.78	55HW Vein
UB-2026-048	37.00	37.60	0.60	0.31	Vein Halo
UB-2026-048	37.60	38.15	0.55	6.56	Untargeted Vein
UB-2026-048	38.15	38.80	0.65	0.02	Untargeted Vein
UB-2026-048	38.80	39.45	0.65	0.01	Untargeted Vein
UB-2026-048	97.30	98.20	0.90	0.01	Vein Halo
UB-2026-048	98.20	99.05	0.85	0.01	Vein Halo
UB-2026-048	99.05	99.60	0.55	13.04	55HW Vein
UB-2026-048	106.65	107.25	0.60	20.26	276 Vein
UB-2026-048	107.25	108.15	0.90	0.39	276 Vein
UB-2026-048	108.15	108.90	0.75	0.19	Vein Halo
UB-2026-050	104.15	104.65	0.50	0.01	Vein Halo
UB-2026-050	104.65	105.15	0.50	0.06	Vein Halo
UB-2026-050	105.15	105.70	0.55	25.20	55HW Vein
UB-2026-050	105.70	106.25	0.55	4.34	55HW Vein
UB-2026-050	108.20	108.70	0.50	13.20	Untargeted Vein
UB-2026-050	108.70	109.25	0.55	0.15	Vein Halo
UB-2026-050	109.25	110.20	0.95	0.39	Vein Halo
UB-2026-050	113.25	113.75	0.50	2.99	Vein Halo
UB-2026-050	113.75	114.40	0.65	15.76	276 Vein
UB-2026-050	114.40	115.15	0.75	14.92	276 Vein
UB-2026-050	115.15	115.70	0.55	0.69	Vein Halo
UB-2026-050	144.70	145.70	1.00	1.04	Vein Halo
UB-2026-050	145.70	146.20	0.50	0.71	Vein Halo
UB-2026-050	146.20	147.00	0.80	7.10	55 Vein
UB-2026-052	113.00	113.85	0.85	38.63	55HW Vein
UB-2026-052	113.85	114.50	0.65	0.17	Vein Halo
UB-2026-052	114.50	115.20	0.70	0.52	Vein Halo
UB-2026-052	129.85	130.35	0.50	5.13	277 Vein
UB-2026-052	130.35	130.90	0.55	1.89	Vein Halo
UB-2026-052	130.90	131.90	1.00	0.50	Vein Halo
UB-2026-054	126.65	127.25	0.60	32.46	278 Vein
UB-2026-054	127.25	127.75	0.50	2.09	Vein Halo
UB-2026-054	127.75	128.65	0.90	2.19	Vein Halo
UB-2026-055	137.95	138.65	0.70	0.21	Vein Halo
UB-2026-055	138.65	139.55	0.90	2.54	276 Vein
UB-2026-055	139.55	140.10	0.55	6.08	276 Vein
UB-2026-057	106.70	107.20	0.50	0.03	Vein Halo
UB-2026-057	107.20	108.15	0.95	6.70	55HW Vein
UB-2026-057	108.15	108.80	0.65	0.48	Vein Halo
UB-2026-058	100.10	100.80	0.70	5.38	55HW Vein
UB-2026-058	100.80	101.45	0.65	6.15	55HW Vein
UB-2026-058	101.45	101.95	0.50	11.90	55HW Vein
UB-2026-058	101.95	102.50	0.55	0.01	Vein Halo
UB-2026-058	106.65	107.15	0.50	0.01	Vein Halo
UB-2026-058	107.15	107.65	0.50	0.01	Vein Halo
UB-2026-058	107.65	108.15	0.50	13.34	276 Vein
UB-2026-058	108.15	108.80	0.65	0.45	Vein Halo
UB-2026-060	94.60	95.30	0.70	0.01	Vein Halo
UB-2026-060	95.30	95.90	0.60	0.04	Vein Halo
UB-2026-060	95.90	96.50	0.60	22.66	55HW Vein
UB-2026-060	96.50	97.05	0.55	30.19	55HW Vein
UB-2026-060	104.15	104.65	0.50	0.05	Vein Halo
UB-2026-060	104.65	105.20	0.55	301.88	276 Vein
UB-2026-060	105.20	105.70	0.50	0.66	Vein Halo
UB-2026-060	105.70	106.25	0.55	0.01	Vein Halo
UB-2026-062	124.60	125.15	0.55	3.70	55HW Vein
UB-2026-062	125.15	125.85	0.70	1.20	55HW Vein
UB-2026-062	125.85	126.55	0.70	0.25	55HW Vein
UB-2026-062	126.55	127.05	0.50	10.23	55HW Vein
Note: The bolded assay samples in this table have been used for the composite assay values and intervals reported in the Highlights section above and in the cross-section intercept labels below. True thickness of structures in this release may range from 50% to 95% of the apparent thicknesses.

Bralorne Gold Project – Drill Collar Locations Table (values rounded to nearest metre)
Drill Hole Name	UTM Easting	UTM Northing	Elevation (m)
SB-2026-032	513761	5624972	1244
SB-2026-033	513761	5624972	1244
SB-2026-034	513761	5624972	1244
SB-2026-035	513761	5624972	1244
SB-2026-036	513761	5624971	1244
SB-2026-037	513761	5624971	1244
SB-2026-038	513761	5624972	1244
UB-2026-046	513571	5624925	1056
UB-2026-048	513569	5624925	1056
UB-2026-050	513570	5624925	1057
UB-2026-052	513570	5624925	1057
UB-2026-054	513571	5624925	1057
UB-2026-055	513571	5624925	1056
UB-2026-057	513570	5624926	1056
UB-2026-058	513570	5624926	1056
UB-2026-060	513569	5624926	1056
UB-2026-062	513571	5624926	1056

Bralorne Gold Project – Drill Collar Orientations Table (negative dip points down from the horizontal)
Drill Hole Name	Azimuth (°)	Dip (°)	Total Depth (m)
SB-2026-032	146.50	-47.50	408.00
SB-2026-033	151.50	-47.80	389.10
SB-2026-034	159.00	-49.90	348.00
SB-2026-035	159.50	-45.00	348.30
SB-2026-036	162.00	-53.70	402.00
SB-2026-037	162.50	-50.00	390.00
SB-2026-038	164.50	-47.50	345.00
UB-2026-046	153.80	-1.25	192.00
UB-2026-048	189.00	5.00	141.00
UB-2026-050	178.80	7.00	147.00
UB-2026-052	169.50	7.50	150.00
UB-2026-054	157.40	9.40	156.00
UB-2026-055	162.00	-1.00	156.00
UB-2026-057	171.00	-1.50	177.30
UB-2026-058	182.50	-2.20	177.00
UB-2026-060	192.70	-3.10	171.00
UB-2026-062	156.60	-9.40	201.00

A Media Snippet accompanying this announcement is available by clicking on this link.

In other news, Talisker has entered into a definitive agreement to acquire all of the outstanding securities of Midex Resources Ltd. (“Midex”) by way of a three-cornered amalgamation (the “Transaction”). Midex is a private junior exploration company focused on gold properties in Ontario. Midex’s main project is the 45,000 hectare, 100%-owned Berens project located north of Red Lake. This project hosts the past-producing Berens River Mine, which operated from 1939 to 1948. Berens River Mine production records indicate total production of 509,000 tonnes of mill feed with an average grade of 8.78 g/t gold and 323 g/t silver¹. Average recoveries were approximately 96.7% for gold and 86.8% for silver. Midex is also the largest claimholder in the Sturgeon Lake greenstone belt, through its 50,000 hectare, 100%-owned Sturgeon Lake and Darkwater gold projects located between Thunder Bay and Pickle Lake. Under the terms of the Transaction, Talisker has agreed to issue 3,000,000 shares of the Company (the “Consideration Shares”) to acquire 100% of Midex shares outstanding. The Consideration Shares will be distributed pro rata to Midex shareholders. Holders of outstanding Midex warrants will receive Talisker replacement warrants adjusted in exercise price and number of underlying shares to reflect the share exchange ratio. Subject to the receipt of approval by Midex shareholders and applicable regulatory approvals, the Transaction is expected to close in late Q4 2026. The Transaction has Midex board and management support, as directors, officers and certain shareholders holding 29% of the issued and outstanding common shares of Midex have entered into voting support agreements with Talisker, pursuant to which they have agreed, among other things, to vote their Midex shares in favour of the Transaction.

Terry Harbort, CEO of Talisker, commented, “The acquisition of Midex brings several highly prospective land packages into the Talisker portfolio and bolsters our long-term growth strategy. Berens in particular shows distinct structural analogies with our Bralorne Gold Project and with significant historic production only coming from one of 20 identified veins, we see significant exploration upside in the future.”

For further information, please contact:

Lindsay Dunlop
Vice President, Investor Relations
lindsay.dunlop@taliskerresources.com
+1 647 274 8975

Qualified Person

The scientific and technical information contained in this news release in relation to the Bralorne Gold Project has been reviewed and approved by Kyle Orr, P.Geo., Vice President, Exploration of Talisker, who is a “Qualified Person” as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Orr is not independent of the Company for the purposes of NI 43-101.

The scientific and technical information contained in this news release regarding historical mine production at Berens River Mine is based solely on reports prepared by prior operators. Kyle Orr, P.Geo, in his capacity as a Qualified Person, has not performed the work or independent data verification necessary to confirm the accuracy or completeness of these historical production figures. Readers are cautioned that this data has not been verified by a Qualified Person and should not place undue reliance on these historical figures.

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker’s flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is producing at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an historic gold producer with significant exploration potential and the Spences Bridge Project where the Company has a significant landholding in the emerging Spences Bridge Gold Belt, and several other early-stage Greenfields projects.

Sample Preparation and QAQC

Drill core in this new release from the Bralorne Gold Project was drilled in NQ size (47.6mm) or HQ size (63.5mm) diameters. Drill core samples are a minimum of 50 cm and a maximum of 150 cm long along the core axis. Samples are focused on an interval of interest, such as a vein or zone of mineralization. Shoulder samples bracket the interval of interest such that a total sampled core length of not less than 3m both above and below the interval of interest must be assigned. Sample QAQC measures of unmarked certified reference materials (CRMs), blanks, and duplicates are inserted into the sample sequence and makeup 10% of the samples submitted to the lab for holes reported in this release. Actlabs performed sample preparation and analyses in Kamloops, British Columbia. Drill core sample preparation includes drying in an oven, crushing of the sample up to 80% passing 2 mm, sample splitting using a riffle splitter, and pulverizing a 1,000 g split to 95% passing 105 microns (ACT code RX1+1000). Gold in diamond drill core is analyzed by fire assay and atomic absorption spectroscopy (AAS) of a 50g sample (ACT code 1A2-50-ORE). Gold assay technique 1A2-50-ORE has an upper detection limit of 100 ppm. Any sample that produces an over-limit gold value via the gold assay technique is sent for gravimetric finish (ACT method 1A3-50) which has an upper detection limit of 10,000 ppm Au. Beginning in August 2026, the analytical laboratory was changed from Actlabs to Paragon Geochemical, and gold analyses were transitioned from conventional fire assay methods to PhotonAssay™ methodology. At Paragon Geochemical, drill core samples were prepared by drying at 100°C, crushing, splitting, and jarring. Samples were crushed to 70% passing 2 mm (PA-PREP) and riffle split to produce a 500 g subsample. Gold analyses were completed on the 500 g jar using the two-cycle PhotonAssay™ method (PA-AU01), which has a reported detection range of approximately 0.015 to 350 ppm Au. Samples returning results above the upper analytical limit were assigned an over-range (OVR) flag and re-analyzed using the high-range PhotonAssay™ method (PAAU02H), which extends the upper analytical limit to 3,500 ppm Au. Samples that remained over-range were subsequently analyzed using the extra high-range PhotonAssay™ method (PAAU02HH), extending the upper analytical limit to 10,000 ppm Au. Where asymmetrically distributed native gold mineralization is observed by the core logging geologist, a “cut-line” may be drawn along the length of the core to guide the core cutter to evenly bisect that mineralization thereby helping to ensure a representative sample. Where no sample cut line is drawn by the geologist the standard procedure is to preserve the oriented core “backside line” or “bottom of hole” mark in the core box. Duplicates were sampled by taking a ¼ core primary sample and a ¼ core as the duplicate sample, thereby leaving a ½ core representative sample in the box. A photo archive exists for all core from before sampling.

Caution Regarding Forward Looking Statements

Certain statements contained in this press release constitute forward-looking information. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Talisker’s current belief or assumptions as to the outcome and timing of such future events. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Talisker. Although such statements are based on reasonable assumptions of Talisker’s management, there can be no assurance that any conclusions or forecasts will prove to be accurate.

Forward looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined, risks relating to variations in grade or recovery rates, risks relating to changes in mineral prices and the worldwide demand for and supply of minerals, risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, including risks relating to the acquisition of the necessary licenses and permits, financing, capitalization and liquidity risks, title and environmental risks and risks relating to the failure to receive all requisite shareholder and regulatory approvals.

The forward-looking information contained in this release is made as of the date hereof, and Talisker is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

^{_____________________________________________
1} https://www.geologyontario.mines.gov.on.ca/mineral-inventory/MDI53C13SE00077

PORT ANGELES, Wash., Oct. 29, 2026 (GLOBE NEWSWIRE) — First Northwest Bancorp (Nasdaq: FNWB) (“First Northwest” or the “Company”), the holding company for First Fed Bank (“First Fed” or the “Bank”), today reported its financial results for the third quarter and nine months ended September 30, 2026. The Company reported a net loss of $743,000 for the third quarter of 2026, compared to net income of $308,000 for the second quarter of 2026 and net income of $802,000 for the third quarter of 2025. Basic and diluted loss per share were $0.08 for the third quarter of 2026, compared to basic and diluted income per share of $0.03 for the second quarter of 2026 and basic and diluted income per share of $0.09 for the third quarter of 2025. 

Management Outlook; President and Chief Executive Officer, Curt Queyrouze:

“We are encouraged by the continued momentum in our core banking franchise during the third quarter, including stable net interest income, modest net interest margin expansion and growth in customer deposits. These results reflect the progress we are making to enhance our funding mix and strengthen the balance sheet. Although reported results were affected by a higher provision for credit losses and the settlement of a previously disclosed legal matter, nonperforming loans declined and allowance coverage improved. With a stable capital position and several strategic and operational initiatives underway, we believe we are building a stronger foundation for improved profitability and long-term shareholder value.”

2026 FINANCIAL RESULTS		3Q 26				2Q 26				3Q 25				2026 YTD				2025 YTD
OPERATING RESULTS (in millions)
Net (loss) income		$	(0.7	)		$	0.3			$	0.8			$	(0.4	)		$	(4.6	)
Net interest income			14.3				14.2				14.6				42.9				42.6
Provision for credit losses			0.7				(0.5	)			(0.7	)			0.3				6.8
Noninterest income			2.2				2.0				2.0				6.2				7.9
Noninterest expense			17.3				16.4				17.4				50.4				50.2
PER SHARE DATA
Basic and diluted (loss) earnings		$	(0.08	)		$	0.03			$	0.09			$	(0.05	)		$	(0.52	)
Book value			15.65				16.66				16.33				15.65				16.33
Tangible book value (1)			15.52				16.52				16.18				15.52				16.18
BALANCE SHEET (in millions)
Total assets		$	2,143			$	2,125			$	2,111			$	2,143			$	2,111
Total securities available for sale			310				287				283				310				283
Total loans			1,594				1,613				1,623				1,594				1,623
Total customer deposits			1,576				1,549				1,549				1,576				1,549
Total brokered deposits			59				59				104				59				104
Total shareholders’ equity			149				158				155				149				155
ASSET QUALITY
Annualized net charge-offs    to average outstanding loans			0.11	%			0.04	%			0.37	%			0.07	%			0.90	%
Nonperforming assets to total assets			0.98				1.05				0.70				0.98				0.70
Allowance for credit losses on loans    to total loans			1.03				1.01				1.00				1.03				1.00
Nonaccrual loan coverage ratio			82.41				78.68				121.17				82.41				121.17
(1)	Non-GAAP financial measure; see “Additional Information – Non-GAAP Financial Measures” later in this release for definitions and a reconciliation to the most comparable GAAP financial measure.

Third Quarter Insights:

• Growth of $27.0 million in customer deposits during the current quarter improved the funding mix.
• Additional investment security purchases during the third quarter of 2026 drove the increase in total assets and partially offset a decline in total loans from the preceding quarter.
• Net interest margin improved to 2.96% for the current quarter compared to 2.95% in the second quarter of 2026, and 2.91% for the third quarter of 2025. 
• First Fed remains well capitalized with a total risk-based capital ratio of 13.3% for the current quarter, 13.4% for the second quarter of 2026, and 13.7% for the third quarter of 2025.

Selected Quarterly Financial Ratios:

		As of or For the Quarter Ended																				As of or For the Nine Months Ended September 30,
		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025				2026				2025
Performance ratios: (1)
	Return on average assets		-0.14	%			0.06	%			0.00	%			0.07	%			0.15	%			-0.03	%			-0.28	%
	Return on average equity		-1.87				0.78				0.02				0.96				2.10				-0.36				-4.03
	Net interest margin (2)		2.96				2.95				3.03				3.00				2.91				2.98				2.83
	Efficiency ratio (3)		105.0				101.3				101.4				92.0				104.9				102.6				99.2
	Equity to total assets		6.95				7.45				7.36				7.46				7.32				6.95				7.32
Tangible performance ratios: (1)
	Tangible common equity to tangible assets (4)		6.89	%			7.39	%			7.30	%			7.40	%			7.26	%			6.89	%			7.26	%
	Return on average tangible common equity (4)		-1.89				0.79				0.02				0.97				2.12				-0.37				-4.07
Capital ratios (First Fed): (5)
	Tier 1 leverage		9.6	%			9.6	%			9.6	%			9.5	%			9.3	%			9.6	%			9.3	%
	Common equity Tier 1		12.3				12.4				12.4				12.5				12.7				12.3				12.7
	Total risk-based		13.3				13.4				13.5				13.6				13.7				13.3				13.7
(1)	Performance ratios are annualized, where appropriate.
(2)	Net interest income divided by average interest-earning assets.
(3)	Total noninterest expense as a percentage of net interest income and total other noninterest income.
(4)	Non-GAAP financial measure; see “Additional Information – Non-GAAP Financial Measures” later in this release for definitions and a reconciliation to the most comparable GAAP financial measure.
(5)	Current period capital ratios are preliminary and subject to finalization of the FDIC Call Report.

Net Interest Income and Margin

Total interest income increased $134,000 to $25.6 million for the third quarter of 2026, compared to $25.5 million for the preceding quarter, and decreased $1.3 million compared to $26.9 million in the third quarter of 2025. Interest income increased during the third quarter of 2026 primarily due to 2026 purchases of investment securities. Average investment securities balances and yields increased compared to the preceding quarter as a result of these purchases. Average consumer and commercial business loan balances increased while average real estate loan balances decreased over the preceding quarter. The yield on interest-earning assets was flat at 5.30% for both the second and third quarters of 2026 as additional income from higher-yielding investment securities and deposits in banks offset a small decline in interest from loans receivable.

Total interest expense was flat at $11.3 million for the second and third quarters of 2026, and decreased $1.1 million compared to $12.3 million in the third quarter of 2025. The deposit mix changed in the third quarter of 2026 with slightly higher rates paid on customer deposits offset by lower average balances on borrowings. As a result of third quarter changes, the total cost of funds decreased 1 basis point to 2.41% compared to the preceding quarter.

The net interest margin increased to 2.96% for the third quarter of 2026, from 2.95% for the preceding quarter and increased from 2.91% for the third quarter of 2025.

Noninterest Income and Expense

Noninterest income increased $169,000 to $2.2 million for the third quarter of 2026, compared to $2.0 million for the second quarter of 2026. The increase was primarily due to a nonrecurring gain recognized upon exercising a historic tax credit partnership redemption option, partially offset by a decline in the valuation of servicing rights on sold loans.

Noninterest expense increased $922,000 to $17.3 million for the third quarter of 2026, compared to $16.4 million for the preceding quarter. The increase was primarily due to a nonrecurring $1.3 million expense for the settlement of the litigation previously disclosed in the Company’s Form 8-K filed September 18, 2026. This increase was partially offset by lower consulting fees recorded in professional fees. Legal fees remain elevated due to the timing of the settlement in the quarter and the Company’s defense of other ongoing legal matters.

Allowance for Credit Losses on Loans (“ACLL”) and Credit Quality

The ACLL increased $79,000 to $16.4 million at September 30, 2026, from $16.3 million at June 30, 2026. The ACLL as a percentage of total loans was 1.03% at September 30, 2026, an increase from 1.01% at June 30, 2026, and an increase from 1.00% at September 30, 2025. A $532,000 loan provision expense for the quarter ended September 30, 2026, was the result of $453,000 in net charge-offs and a $264,000 increase in reserves on individually evaluated loans, partially offset by a $185,000 decrease in the overall pooled loan reserve. The change in pooled loan reserve was driven by lower loss factors applied to multi-family and auto loans combined with decreased loan balances in commercial business loans.

Nonperforming loans decreased $842,000 to $19.9 million at September 30, 2026, from $20.7 million at June 30, 2026. Current quarter activity included principal payments totaling $1.4 million and net charge-offs on nonperforming loans totaling $419,000. The decreases were partially offset by the transition into nonaccrual status of loans totaling $1.0 million across multiple loan categories. ACLL to nonperforming loans increased slightly to 82% at September 30, 2026, from 79% at June 30, 2026, reflecting a higher ACLL balance and lower nonperforming loan balances.

Classified loans increased $593,000 to $26.1 million at September 30, 2026, from $25.5 million at June 30, 2026, primarily due to $2.5 million of new downgrades across multiple loan categories. The increase was partially offset by principal payments totaling $1.4 million and net charge-offs totaling $419,000. Four collateral-dependent loans totaling $17.4 million account for 67% of the classified loan balance at September 30, 2026.

	For the Quarter Ended
ACLL ($ in thousands)	September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
Balance at beginning of period	$	16,309			$	16,823			$	16,987			$	16,203			$	18,345
Charge-offs:
Commercial real estate		—				—				(3	)			(329	)			(656	)
Construction and land		(110	)			(200	)			(171	)			(1,027	)			(483	)
Auto and other consumer		(171	)			(125	)			(276	)			(123	)			(106	)
Commercial business		(273	)			(34	)			(133	)			(964	)			(1,005	)
Total charge-offs		(554	)			(359	)			(583	)			(2,443	)			(2,250	)
Recoveries:
Commercial real estate		—				—				—				—				6
Auto and other consumer		91				109				50				34				47
Commercial business		10				73				382				2,727				675
Total recoveries		101				182				432				2,761				728
Net loan (charge-offs) recoveries		(453	)			(177	)			(151	)			318				(1,522	)
Provision for (recapture of) credit losses on loans		532				(337	)			(13	)			466				(620	)
Balance at end of period	$	16,388			$	16,309			$	16,823			$	16,987			$	16,203
Average total loans	$	1,578,190			$	1,604,872			$	1,613,526			$	1,622,476			$	1,650,340
Annualized net charge-offs (recoveries) to average    outstanding loans		0.11	%			0.04	%			0.04	%			-0.08	%			0.37	%

Asset Quality ($ in thousands)		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
Nonaccrual loans:
	One-to-four family	$	1,608			$	1,627			$	2,521			$	2,272			$	2,345
	Multi-family		17				—				—				—				—
	Commercial real estate		9,213				9,449				9,619				9,745				3,439
	Construction and land		3,598				4,164				4,164				5,146				6,037
	Home equity		158				159				53				53				9
	Auto and other consumer		1,018				1,332				1,280				1,086				1,072
	Commercial business		4,274				3,997				4,062				4,293				470
	Total nonaccrual loans		19,886				20,728				21,699				22,595				13,372
Other real estate owned			1,101				1,568				1,380				1,380				1,377
Total nonperforming assets		$	20,987			$	22,296			$	23,079			$	23,975			$	14,749
Nonaccrual loans as a % of total loans			1.25	%			1.28	%			1.33	%			1.39	%			0.82	%
Nonperforming assets as a % of total assets (1)			0.98				1.05				1.08				1.14				0.70
ACLL as a % of total loans			1.03				1.01				1.03				1.04				1.00
ACLL as a % of nonaccrual loans			82.41				78.68				77.53				75.18				121.17
Total past due loans to total loans			1.44				1.09				1.18				1.21				0.88
(1)	Nonperforming assets consists of nonperforming loans (which include nonaccruing loans and accruing loans more than 90 days past due), other real estate owned and repossessed assets.

Financial Condition and Capital

Continued disciplined balance sheet management and deposit growth resulted in reduced reliance on higher-cost brokered deposits while maintaining stable capital levels.

Investment securities increased $23.2 million, or 8.1%, to $310.2 million at September 30, 2026, compared to $287.0 million three months earlier, and increased $27.6 million compared to $282.6 million at September 30, 2025. Purchases totaling $44.4 million were partially offset by an $11.9 million increase in net unrealized losses, maturities totaling $4.4 million and regular principal payments totaling $4.9 million during the third quarter of 2026. The estimated average life of the securities portfolio was approximately 6.9 years at September 30, 2026, 6.4 years at the preceding quarter end and 6.9 years at the end of the third quarter of 2025. The effective duration of the portfolio was approximately 4.2 years at September 30, 2026, compared to 4.6 years at the preceding quarter end and 4.8 years at the end of the third quarter of 2025.

Investment Securities ($ in thousands)	September 30, 2026			June 30, 2026			September 30, 2025			Three Month % Change			One Year % Change
Available for Sale at Fair Value
Municipal bonds	$	72,758		$	79,990		$	79,621		-9.0	%		-8.6	%
U.S. government agency issued asset-backed    securities (ABS agency)		11,170			11,371			12,169		-1.8			-8.2
Corporate issued asset-backed securities (ABS    corporate)		21,088			6,615			9,881		218.8			113.4
Corporate issued debt securities (Corporate    debt)		60,191			50,991			43,339		18.0			38.9
U.S. Small Business Administration securities    (SBA)		4,923			5,362			6,977		-8.2			-29.4
Mortgage-backed securities:
U.S. government agency issued mortgage-    backed securities (MBS agency)		91,217			95,002			94,203		-4.0			-3.2
Non-agency issued mortgage-backed    securities (MBS non-agency)		48,841			37,697			36,418		29.6			34.1
Total securities available for sale	$	310,188		$	287,028		$	282,608		8.1			9.8

Net loans receivable, excluding loans held for sale, decreased $19.9 million, or 1.2%, to $1.58 billion at September 30, 2026, from $1.60 billion at June 30, 2026, and decreased $30.6 million, or 1.9%, from $1.61 billion one year prior. Construction loans that converted into fully amortizing loans during the quarter totaled $2.4 million. Regular payments of $34.0 million, loan payoffs of $42.4 million and charge-offs totaling $554,000 outpaced new loan funding totaling $58.1 million and draws on existing loans totaling $18.0 million. Participation in the Northpointe Bank Mortgage Purchase Program (“Northpoint Bank MPP”) decreased $20.0 million while purchased consumer loans increased $322,000 during the current quarter.

Loans ($ in thousands)	September 30, 2026				June 30, 2026				September 30, 2025			Three Month % Change			One Year % Change
Real Estate:
One-to-four family	$	353,620		$	357,077			$	382,486			-1.0	%		-7.5	%
Multi-family		245,236			255,813				296,321			-4.1			-17.2
Commercial real estate		420,161			402,798				396,519			4.3			6.0
Construction and land		62,491			61,697				67,793			1.3			-7.8
Total real estate loans		1,081,508			1,077,385				1,143,119			0.4			-5.4
Consumer:
Home equity		94,171			90,014				86,629			4.6			8.7
Auto and other consumer		296,217			294,982				280,224			0.4			5.7
Total consumer loans		390,388			384,996				366,853			1.4			6.4
Commercial business		122,031			151,000				113,160			-19.2			7.8
Total loans receivable		1,593,927			1,613,381				1,623,132			-1.2			-1.8
Less:
Derivative basis adjustment		353			(10	)			(896	)		3,630.0			139.4
Allowance for credit losses on loans		16,388			16,309				16,203			0.5			1.1
Total loans receivable, net	$	1,577,186		$	1,597,082			$	1,607,825			-1.2			-1.9

Total deposits increased $27.0 million to $1.63 billion at September 30, 2026, compared to $1.61 billion at June 30, 2026, and decreased $18.9 million compared to $1.65 billion one year prior. During the third quarter of 2026, total customer deposit balances increased $27.0 million and there was no change in brokered deposit balances. The customer deposit mix reflects increased average CD, money market and demand account balances while average balances of savings accounts decreased compared to the preceding quarter. The rates paid on customer interest-bearing deposits increased 7 basis points to 2.39% for the current quarter, compared to 2.32% for the second quarter of 2026. The deposit mix compared to September 30, 2025, reflects an increase in average balances of customer accounts to CD, savings and money market accounts, with an overall $29.6 million increase to average total customer balances. A $45.2 million decrease in the average balance of brokered CDs was the main driver for the year-over-year decrease in total deposits. Rates paid on total interest-bearing deposit accounts decreased 14 basis points compared to the same quarter one year ago.

Deposits ($ in thousands)	September 30, 2026			June 30, 2026			September 30, 2025			Three Month % Change			One Year % Change
Noninterest-bearing demand deposits	$	253,385		$	244,699		$	255,366		3.5	%		-0.8	%
Interest-bearing demand deposits		146,932			147,019			146,373		-0.1			0.4
Money market accounts		466,782			462,208			475,614		1.0			-1.9
Savings accounts		243,962			241,711			232,831		0.9			4.8
Certificates of deposit, customer		464,732			453,140			438,780		2.6			5.9
Certificates of deposit, brokered		58,615			58,615			104,363		0.0			-43.8
Total deposits	$	1,634,408		$	1,607,392		$	1,653,327		1.7			-1.1

Total shareholders’ equity decreased to $148.8 million at September 30, 2026, compared to $158.3 million three months earlier, due to decreases in the after-tax fair market values of the available-for-sale investment securities portfolio of $9.3 million and a net loss of $743,000, partially offset by the after-tax fair value of the investment portfolio hedge of $332,000. No shares of common stock were repurchased under the Company’s April 2024 Stock Repurchase Plan (the “Repurchase Plan”) during the quarter ended September 30, 2026. There are 846,123 shares that remain available for repurchase under the Repurchase Plan.

Capital levels for both the Company and the Bank remain in excess of applicable requirements and the Bank was categorized as “well-capitalized” at September 30, 2026. Preliminary calculations of Common Equity Tier 1 and Total Risk-Based Capital Ratios at September 30, 2026, for the Bank were 12.3% and 13.3%, respectively.

2026 Awards/Recognition
Forbes Best-in-State Banks	Sound Publishing:
Bellingham Best of the Northwest – Best Bank Gold	Best Bank in Clallam County
	Best Lender in the West End

About the Company
First Northwest Bancorp (Nasdaq: FNWB) is a financial holding company engaged in investment activities including the business of its subsidiary, First Fed Bank. First Fed is a Pacific Northwest-based financial institution which has served its customers and communities since 1923. Currently First Fed has 16 locations in Washington state including 11 full-service branches. First Fed’s business and operating strategy is focused on building sustainable earnings by delivering a full array of financial products and services for individuals, small businesses, non-profit organizations and commercial customers. First Northwest has also strategically invested in partnerships focused on developing modern financial solutions and a boutique investment banking/accelerator firm. These investments underscore the Company’s commitment to innovation and growth in the financial services sector. First Northwest Bancorp was incorporated in 2012 and completed its initial public offering in 2015 under the ticker symbol FNWB. The Company is headquartered in Port Angeles, Washington.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, expectations of the business environment in which we operate, projections of future performance and execution on certain strategies, perceived opportunities in the market, potential future credit experience, including our ability to collect, and include, but are not limited to, statements about our plans, objectives, expectations and intentions that are not historical facts, and other statements often identified by words such as “believes,” “expects,” “anticipates,” “estimates,” or similar expressions. These forward-looking statements are based upon current management beliefs and expectations and may, therefore, involve risks and uncertainties, many of which are beyond our control. Our actual results, performance, or achievements may differ materially from those suggested, expressed, or implied by forward-looking statements as a result of a wide variety of factors including, but not limited to: increased competitive pressures; changes in the interest rate environment; the credit risks of lending activities; pressures on liquidity, including as a result of withdrawals of deposits, declines in the value of our investment portfolio or changes in interest rates; risks related to overall economic conditions; geopolitical events; legislative, regulatory, and policy changes; legal proceedings, regulatory investigations and their resolutions; and other factors described in the Company’s latest Annual Report on Form 10-K under the section entitled “Risk Factors,” and other filings with the Securities and Exchange Commission (“SEC”), which are available on our website at www.ourfirstfed.com and on the SEC’s website at www.sec.gov.

Any of the forward-looking statements that we make in this press release and in the other public statements we make may turn out to be incorrect because of the inaccurate assumptions we might make, because of the factors illustrated above or because of other factors that we cannot foresee. Because of these and other uncertainties, our actual future results may be materially different from those expressed or implied in any forward-looking statements made by or on our behalf and the Company’s operating and stock price performance may be negatively affected. Therefore, these factors should be considered in evaluating the forward-looking statements, and undue reliance should not be placed on such statements. We do not undertake and specifically disclaim any obligation to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements, except as required by law. These risks could cause our actual results for 2026 and beyond to differ materially from those expressed in or implied by any forward-looking statements by, or on behalf of, us and could negatively affect the Company’s operations and stock price performance.

For More Information Contact:
Curt Queyrouze, President and Chief Executive Officer
Phyllis Nomura, Chief Financial Officer and EVP
IRGroup@ourfirstfed.com
360-457-0461

FIRST NORTHWEST BANCORP AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS (Dollars in thousands, except share data) (Unaudited)
	September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
ASSETS
Cash and due from banks	$	17,986			$	14,649			$	16,548			$	15,530			$	15,688
Interest-earning deposits in banks		85,639				83,709				87,588				69,587				63,482
Investment securities available for sale, at fair value    (amortized cost at each period end of $348,325,    $313,215, $299,707, $295,849 and $310,545)		310,188				287,028				272,985				270,310				282,608
Loans held for sale		300				1,286				1,140				1,063				2,154
Loans receivable (net of allowance for credit losses    on loans at each period end of $16,388, $16,309,    $16,823, $16,987, and $16,203)		1,577,186				1,597,082				1,612,979				1,612,028				1,607,825
Federal Home Loan Bank (FHLB) stock, at cost		13,211				13,279				13,927				13,105				10,856
Accrued interest receivable		8,197				7,181				7,051				6,498				8,160
Premises and equipment, net		9,270				9,160				8,591				8,464				8,788
Servicing rights on sold loans, at fair value		2,776				3,012				2,999				3,014				3,093
Bank-owned life insurance (“BOLI”), net		43,762				43,305				42,850				42,382				41,889
Equity and partnership investments		15,331				15,441				15,452				15,489				15,048
Goodwill and other intangible assets, net		1,062				1,062				1,062				1,062				1,080
Deferred tax asset, net		16,937				13,664				13,898				13,638				14,168
Right-of-use (“ROU”) asset, net		14,975				15,057				15,316				15,596				15,494
Prepaid expenses and other assets		25,742				19,920				21,057				20,129				21,040
Total assets	$	2,142,562			$	2,124,835			$	2,133,443			$	2,107,895			$	2,111,373
LIABILITIES AND SHAREHOLDERS’ EQUITY
Deposits	$	1,634,408			$	1,607,392			$	1,601,582			$	1,599,101			$	1,653,327
Borrowings		311,694				313,177				328,160				308,143				259,625
Accrued interest payable		145				151				280				1,223				1,145
Lease liability, net		15,968				16,039				16,250				16,439				16,071
Accrued expenses and other liabilities		28,795				28,260				27,514				24,301				24,321
Advances from borrowers for taxes and insurance		2,716				1,503				2,691				1,424				2,356
Total liabilities		1,993,726				1,966,522				1,976,477				1,950,631				1,956,845
Shareholders’ Equity
Preferred stock, $0.01 par value, authorized    5,000,000 shares, no shares issued or    outstanding		—				—				—				—				—
Common stock, $0.01 par value, 75,000,000    shares authorized; issued and outstanding at    each period end: 9,508,205; 9,504,441;    9,499,300; 9,467,925; and 9,462,150		95				95				95				95				94
Additional paid-in capital		94,075				93,986				93,854				93,803				93,646
Retained earnings		91,272				92,015				91,707				91,699				91,317
Accumulated other comprehensive loss, net of    tax		(31,165	)			(22,177	)			(22,920	)			(22,398	)			(24,429	)
Unearned employee stock ownership plan    (ESOP) shares		(5,441	)			(5,606	)			(5,770	)			(5,935	)			(6,100	)
Total shareholders’ equity		148,836				158,313				156,966				157,264				154,528
Total liabilities and shareholders’ equity	$	2,142,562			$	2,124,835			$	2,133,443			$	2,107,895			$	2,111,373

FIRST NORTHWEST BANCORP AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in thousands, except per share data) (Unaudited)
	For the Quarter Ended																				For the Nine Months Ended
	September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025				September 30, 2026				September 30, 2025
INTEREST INCOME
Interest and fees on loans receivable	$	21,815			$	21,997			$	22,000			$	22,431			$	22,814			$	65,812			$	67,859
Interest on investment securities		3,067				2,723				2,585				2,971				3,244				8,375				10,513
Interest on deposits in banks		464				453				467				473				570				1,384				1,572
FHLB dividends		243				282				282				262				282				807				920
Total interest income		25,589				25,455				25,334				26,137				26,910				76,378				80,864
INTEREST EXPENSE
Deposits		8,493				8,033				7,930				8,648				9,083				24,456				28,372
Borrowings		2,778				3,249				2,964				2,799				3,258				8,991				9,883
Total interest expense		11,271				11,282				10,894				11,447				12,341				33,447				38,255
Net interest income		14,318				14,173				14,440				14,690				14,569				42,931				42,609
PROVISION FOR CREDIT LOSSES
Provision for (recapture of) credit losses on loans		532				(337	)			(13	)			466				(620	)			182				6,854
Provision for (recapture of) credit losses on unfunded commitments		207				(203	)			91				97				(53	)			95				(102	)
Provision for (recapture of) credit losses		739				(540	)			78				563				(673	)			277				6,752
Net interest income after provision    for (recapture of) credit losses		13,579				14,713				14,362				14,127				15,242				42,654				35,857
NONINTEREST INCOME
Loan and deposit service fees		1,150				1,107				1,122				1,044				1,114				3,379				3,315
Sold loan servicing fees and servicing rights mark-to-market		(47	)			162				127				57				85				242				372
Net gain (loss) on sale of loans		40				73				76				96				(39	)			189				16
Increase in BOLI cash surrender value		457				455				468				493				539				1,380				1,396
Income from BOLI death benefit, net		—				—				—				—				—				—				1,059
Other income		574				208				215				2,000				303				997				1,791
Total noninterest income		2,174				2,005				2,008				3,690				2,002				6,187				7,949
NONINTEREST EXPENSE
Compensation and benefits		8,185				8,054				8,232				8,042				8,353				24,471				20,766
Data processing		1,943				1,702				2,228				1,990				1,941				5,873				5,878
Occupancy and equipment		1,512				1,538				1,565				1,539				1,505				4,615				4,604
Supplies, postage, and telephone		305				384				298				332				344				987				988
Regulatory assessments and state taxes		548				581				534				688				558				1,663				1,538
Advertising		278				245				304				290				282				827				846
Professional fees		1,915				2,305				2,026				1,957				2,668				6,246				4,894
FDIC insurance premium		381				387				363				424				411				1,131				1,308
Legal settlement		1,300				—				—				—				(10	)			1,300				5,740
Other expense		948				1,197				1,134				1,640				1,338				3,279				3,593
Total noninterest expense		17,315				16,393				16,684				16,902				17,390				50,392				50,155
(Loss) income before (benefit    from) provision for income taxes		(1,562	)			325				(314	)			915				(146	)			(1,551	)			(6,349	)
(Benefit from) provision for income taxes		(819	)			17				(320	)			533				(948	)			(1,122	)			(1,776	)
Net (loss) income	$	(743	)		$	308			$	6			$	382			$	802			$	(429	)		$	(4,573	)
Basic and diluted (loss) earnings per common share	$	(0.08	)		$	0.03			$	–			$	0.04			$	0.09			$	(0.05	)		$	(0.52	)
Diluted weighted average common shares outstanding		8,903,832				8,930,663				8,894,998				8,860,060				8,813,632				8,877,432				8,779,708

FIRST NORTHWEST BANCORP AND SUBSIDIARY ADDITIONAL INFORMATION (Dollars in thousands) (Unaudited)
Selected Loan Detail	September 30, 2026			June 30, 2026			March 31, 2026			December 31, 2025			September 30, 2025
Construction and land loans breakout
1-4 Family construction	$	13,994		$	5,682		$	18,802		$	21,954		$	29,961
Multifamily construction		18,584			14,826			12,144			10,109			15,660
Nonresidential construction		24,952			35,749			25,758			23,005			16,484
Land and development		4,961			5,440			5,643			6,200			5,688
Total construction and land loans	$	62,491		$	61,697		$	62,347		$	61,268		$	67,793
Auto and other consumer loans breakout
Triad Manufactured Home loans	$	133,054		$	131,367		$	131,406		$	132,287		$	133,425
Woodside auto loans		153,421			152,748			147,444			137,678			131,800
First Help auto loans		5,632			6,430			7,570			8,491			9,561
Other auto loans		257			346			468			586			767
Other consumer loans		3,853			4,091			4,072			4,460			4,671
Total auto and other consumer loans	$	296,217		$	294,982		$	290,960		$	283,502		$	280,224
Commercial business loans breakout
Northpointe Bank MPP	$	24,644		$	44,602		$	41,951		$	18,941		$	–
Secured lines of credit		24,747			34,485			40,991			39,783			43,081
Unsecured lines of credit		2,597			2,953			3,351			2,901			2,580
SBA loans		6,724			6,818			5,505			5,645			6,347
Other commercial business loans		63,319			62,142			60,793			63,041			61,152
Total commercial business loans	$	122,031		$	151,000		$	152,591		$	130,311		$	113,160

Loans by Collateral and Unfunded Commitments	September 30, 2026			June 30, 2026			March 31, 2026			December 31, 2025			September 30, 2025
One-to-four family construction	$	19,639		$	20,583		$	18,571		$	23,815		$	31,627
All other construction and land		42,852			41,873			44,000			37,334			36,161
One-to-four family first mortgage		401,389			425,021			440,576			431,222			415,670
One-to-four family junior liens		19,018			19,986			21,169			21,003			20,568
One-to-four family revolving open-end		68,531			62,411			57,027			56,365			58,486
Commercial real estate, owner occupied:
Health care		31,244			31,522			28,177			28,488			28,794
Office		21,182			22,895			18,953			19,216			18,499
Warehouse		9,202			9,270			7,549			7,608			7,684
Other		74,961			71,064			72,556			71,313			73,562
Commercial real estate, non-owner occupied:
Office		40,034			36,297			36,657			40,311			40,917
Retail		51,685			52,465			53,519			50,494			50,839
Hospitality		63,005			62,352			62,729			63,113			63,953
Other		121,306			113,320			115,367			112,307			106,991
Multi-family residential		246,270			256,853			272,025			289,581			297,379
Commercial business loans		55,173			61,958			61,247			66,264			68,062
Commercial agriculture and fishing loans		31,886			30,197			27,982			25,842			23,346
State and political subdivision obligations		333			333			333			333			369
Consumer automobile loans		159,316			159,519			155,443			146,708			142,064
Consumer loans secured by other assets		135,280			133,899			133,825			134,826			136,073
Consumer loans unsecured		1,621			1,563			1,691			1,969			2,088
Total loans	$	1,593,927		$	1,613,381		$	1,629,396		$	1,628,112		$	1,623,132
Unfunded commitments under lines of credit or existing loans	$	169,974		$	164,614		$	166,899		$	167,489		$	158,118

FIRST NORTHWEST BANCORP AND SUBSIDIARY NET INTEREST MARGIN ANALYSIS (Unaudited)
		Three Months Ended
		September 30, 2026											June 30, 2026											September 30, 2025
(dollars in thousands)		Average Balance Outstanding				Interest Earned/ Paid			Yield/ Rate				Average Balance Outstanding				Interest Earned/ Paid			Yield/ Rate				Average Balance Outstanding				Interest Earned/ Paid			Yield/ Rate
Interest-earning assets:
Loans receivable, net (1) (2)		$	1,561,983			$	21,815			5.54	%		$	1,588,321			$	21,997			5.55	%		$	1,632,684			$	22,814			5.54	%
Total investment securities			294,960				3,067			4.13				276,147				2,723			3.96				293,723				3,244			4.38
FHLB dividends			9,943				243			9.70				12,020				282			9.41				12,810				282			8.73
Interest-earning deposits in banks			49,136				464			3.75				48,783				453			3.72				50,150				570			4.51
	Total interest-earning assets (3)		1,916,022				25,589			5.30				1,925,271				25,455			5.30				1,989,367				26,910			5.37
Noninterest-earning assets			143,191											143,007											146,042
	Total average assets	$	2,059,213										$	2,068,278										$	2,135,409
Interest-bearing liabilities:
Interest-bearing demand deposits		$	142,597			$	99			0.28			$	141,339			$	83			0.24			$	141,469			$	52			0.15
Money market accounts			466,389				2,642			2.25				455,356				2,451			2.16				464,265				2,832			2.42
Savings accounts			241,159				974			1.60				243,735				921			1.52				231,431				914			1.57
Certificates of deposit, customer			461,588				4,189			3.60				449,938				4,024			3.59				443,312				4,175			3.74
Certificates of deposit, brokered			58,745				589			3.98				51,788				554			4.29				103,959				1,110			4.24
	Total interest-bearing deposits (4)		1,370,478				8,493			2.46				1,342,156				8,033			2.40				1,384,436				9,083			2.60
Advances			204,364				2,159			4.19				252,230				2,633			4.19				265,554				2,913			4.35
Subordinated debt			34,685				619			7.08				34,668				616			7.13				34,617				345			3.95
Total interest-bearing liabilities			1,609,527				11,271			2.78				1,629,054				11,282			2.78				1,684,607				12,341			2.91
Noninterest-bearing deposits (4)			249,784											237,762											251,448
Other noninterest-bearing liabilities			42,502											43,529											47,978
	Total average liabilities		1,901,813											1,910,345											1,984,033
Average equity			157,400											157,933											151,376
	Total average liabilities and equity	$	2,059,213										$	2,068,278										$	2,135,409
Net interest income						$	14,318										$	14,173										$	14,569
Net interest rate spread										2.52											2.52											2.46
Net earning assets		$	306,495										$	296,217										$	304,760
Net interest margin (5)										2.96											2.95											2.91
Average interest-earning assets to average interest- bearing liabilities			119.0	%										118.2	%										118.1	%
(1)	The average loans receivable, net balances include nonaccrual loans.
(2)	Interest earned on loans receivable includes net deferred costs of $841,000, $775,000 and $410,000 for the three months ended September 30, 2026, June 30, 2026 and September 30, 2025, respectively.
(3)	Includes interest-earning deposits (cash) at other financial institutions.
(4)	Cost of all deposits, including noninterest-bearing demand deposits, was 2.08%, 2.04%, and 2.20% for the three months ended September 30, 2026, June 30, 2026 and September 30, 2025, respectively.
(5)	Net interest income divided by average interest-earning assets.

FIRST NORTHWEST BANCORP AND SUBSIDIARY
ADDITIONAL INFORMATION
(Unaudited)

Non-GAAP Financial Measures
This press release contains financial measures that are not in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Non-GAAP financial measures are presented where management believes the information will help investors understand the Company’s results of operations or financial position and assess trends. Where non-GAAP financial measures are used, the comparable GAAP financial measure is also provided. These disclosures should not be viewed as a substitute for operating results determined in accordance with GAAP, and are not necessarily comparable to non-GAAP performance measures that may be presented by other companies. Other banking companies may use names similar to those the Company uses for the non-GAAP financial measures the Company discloses, but may calculate them differently. Investors should understand how the Company and other companies each calculate their non-GAAP financial measures when making comparisons. Reconciliations of the GAAP and non-GAAP measures are presented below.

Calculations Based on Tangible Common Equity:

		For the Quarter Ended																				For the Nine Months Ended
($ in thousands, except per share data)		September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025				September 30, 2026				September 30, 2025
Total shareholders’ equity		$	148,836			$	158,313			$	156,966			$	157,264			$	154,528			$	148,836			$	154,528
Less: Goodwill and other intangible assets			1,062				1,062				1,062				1,062				1,080				1,062				1,080
	Disallowed non-mortgage loan servicing rights		226				247				312				302				317				226				317
Total tangible common equity		$	147,548			$	157,004			$	155,592			$	155,900			$	153,131			$	147,548			$	153,131
Total assets		$	2,142,562			$	2,124,835			$	2,133,443			$	2,107,895			$	2,111,373			$	2,142,562			$	2,111,373
Less: Goodwill and other intangible assets			1,062				1,062				1,062				1,062				1,080				1,062				1,080
	Disallowed non-mortgage loan servicing rights		226				247				312				302				317				226				317
Total tangible assets		$	2,141,274			$	2,123,526			$	2,132,069			$	2,106,531			$	2,109,976			$	2,141,274			$	2,109,976
Average shareholders’ equity		$	157,400			$	157,933			$	159,532			$	157,588			$	151,376			$	158,281			$	151,538
Less: Average goodwill and other intangible assets			1,062				1,062				1,062				1,080				1,081				1,062				1,081
	Average disallowed non-mortgage loan servicing rights		247				311				302				317				371				286				403
Total average tangible common equity		$	156,091			$	156,560			$	158,168			$	156,191			$	149,924			$	156,933			$	150,054
Net (loss) income		$	(743	)		$	308			$	6			$	382			$	802			$	(429	)		$	(4,573	)
Common shares outstanding			9,508,205				9,504,441				9,499,300				9,467,925				9,462,150				9,508,205				9,462,150
GAAP Ratios:
	Equity to total assets		6.95	%			7.45	%			7.36	%			7.46	%			7.32	%			6.95	%			7.32	%
	Return on average equity		-1.87	%			0.78	%			0.02	%			0.96	%			2.10	%			-0.36	%			-4.03	%
	Book value per common share	$	15.65			$	16.66			$	16.52			$	16.61			$	16.33			$	15.65			$	16.33
Non-GAAP Ratios:
	Tangible common equity to tangible assets (1)		6.89	%			7.39	%			7.30	%			7.40	%			7.26	%			6.89	%			7.26	%
	Return on average tangible common equity (1)		-1.89	%			0.79	%			0.02	%			0.97	%			2.12	%			-0.37	%			-4.07	%
	Tangible book value per common share (1)	$	15.52			$	16.52			$	16.38			$	16.47			$	16.18			$	15.52			$	16.18
(1)	We believe that the use of tangible equity and tangible assets improves the comparability to other institutions that have not engaged in acquisitions that resulted in recorded goodwill and other intangibles.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/43935da2-1fac-45d3-aaa6-7e49c5d48c82
https://www.globenewswire.com/NewsRoom/AttachmentNg/497cc8f7-e380-4650-b771-abaf7d6f38a0
https://www.globenewswire.com/NewsRoom/AttachmentNg/5267f335-4f02-4e57-903c-642aeea8ee39
https://www.globenewswire.com/NewsRoom/AttachmentNg/a1bbf68e-d1dd-4a67-828e-4c138f1be953